

Atherogenic lipoprotein phenotype. A proposed genetic risk.

Circulation

82, 495-506

DOI: [10.1161/01.cir.82.2.495](https://doi.org/10.1161/01.cir.82.2.495)

Citation Report

#	ARTICLE	IF	CITATIONS
1	New lipoprotein profiles and coronary heart disease. Improving precision of risk.. Circulation, 1990, 82, 649-651.	1.6	11
2	The tangled web of coronary risk factors. American Journal of Medicine, 1991, 90, S36-S41.	0.6	67
3	Prevention and regression of atherosclerosis with drug therapy. Clinical Cardiology, 1991, 14, 40-47.	0.7	3
4	Low-density lipoprotein subclass phenotypes and familial combined hyperlipidemia. Diabetes/metabolism Reviews, 1991, 7, 173-177.	0.2	5
5	Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil. Journal of Internal Medicine, 1991, 229, 427-434.	2.7	54
6	Linkage analysis of low-density lipoprotein subclass phenotypes and the apolipoprotein B gene. Genetic Epidemiology, 1991, 8, 269-275.	0.6	28
7	Lack of evidence for linkage between low-density lipoprotein subclass phenotypes and the apolipoprotein B locus in familial combined hyperlipidemia. Genetic Epidemiology, 1991, 8, 287-297.	0.6	34
8	Plasma triglyceride and coronary heart disease.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991, 11, 2-14.	3.8	651
9	Concordance for Dyslipidemic Hypertension in Male Twins. JAMA - Journal of the American Medical Association, 1991, 265, 2079.	3.8	72
10	The Helsinki Heart Study: Central Findings and Clinical Implications. Annals of Medicine, 1991, 23, 155-159.	1.5	97
11	Two Different Views of the Relationship of Hypertriglyceridemia to Coronary Heart Disease. Archives of Internal Medicine, 1992, 152, 28.	4.3	102
12	Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes.. Circulation, 1992, 85, 30-36.	1.6	81
13	Joint lipid risk factors and coronary heart disease.. Circulation, 1992, 85, 365-367.	1.6	16
14	LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992, 12, 1496-1502.	3.8	299
15	Multiple Risk Factors in Cardiovascular Disease. Medical Science Symposia Series, 1992, , .	0.0	0
16	LDL particle size distribution. Results from the Framingham Offspring Study.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992, 12, 1410-1419.	3.8	203
17	Multiple Metabolic Syndrome: Aspects of Genetic Epidemiology and Molecular Genetics. Annals of Medicine, 1992, 24, 461-464.	1.5	23
18	Familial Dyslipidaemic Hypertension and Other Multiple Metabolic Syndromes. Annals of Medicine, 1992, 24, 469-475.	1.5	33

#	ARTICLE	IF	CITATIONS
19	Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel.. <i>Circulation</i> , 1992, 86, 839-848.	1.6	64
20	Low density lipoprotein particle size and coronary artery disease.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1992, 12, 187-195.	3.8	480
21	Genetic Epidemiology of Low-Density Lipoprotein Subclass Phenotypes. <i>Annals of Medicine</i> , 1992, 24, 477-481.	1.5	50
22	Prevalence of cardiovascular risk factors in rural and urban Costa Rica.. <i>Circulation</i> , 1992, 85, 648-658.	1.6	52
23	Gene-Diet Interactions in Lipoprotein Metabolism1. <i>Monographs in Human Genetics</i> , 1992, 14, 325-349.	0.5	5
24	Linkage of atherogenic lipoprotein phenotype to the low density lipoprotein receptor locus on the short arm of chromosome 19.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 708-712.	3.3	150
25	Bimodality of plasma apolipoprotein B levels in familial combined hyperlipidemia. <i>Atherosclerosis</i> , 1992, 92, 67-77.	0.4	66
26	Differential effects of nicotinic acid in subjects with different LDL subclass patterns. <i>Atherosclerosis</i> , 1992, 95, 69-76.	0.4	141
27	Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.. <i>Circulation</i> , 1992, 85, 37-45.	1.6	1,249
28	Lipoprotein and apolipoprotein profile in men with ischemic stroke. Role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism.. <i>Stroke</i> , 1992, 23, 1556-1562.	1.0	240
29	The Good, The Bad, and The Ugly in Diabetic Diets. <i>Endocrinology and Metabolism Clinics of North America</i> , 1992, 21, 237-279.	1.2	8
30	Lipid metabolism: metabolic consequences of moderate hypertriglyceridemia. , 1992, , 59-70.		0
31	Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. <i>Kidney International</i> , 1992, 41, 1394-1399.	2.6	85
32	Prevalence of coronary artery disease in Asian Indians. <i>American Journal of Cardiology</i> , 1992, 70, 945-949.	0.7	211
33	Epidemiology of triglycerides: A view from Framingham. <i>American Journal of Cardiology</i> , 1992, 70, H3-H9.	0.7	286
34	Hypertriglyceridemia: Risks and perspectives. <i>American Journal of Cardiology</i> , 1992, 70, H19-H25.	0.7	30
35	Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. <i>American Journal of Cardiology</i> , 1992, 70, 135-140.	0.7	43
36	Influence of n-3 fatty acids from fish oils on concentration of high- and low-density lipoprotein subfractions and their lipid and apolipoprotein composition. <i>Clinical Biochemistry</i> , 1992, 25, 338-340.	0.8	22

#	ARTICLE	IF	CITATIONS
38	Effects of cholestyramine and acipimox on sub fractions of plasma low density lipoprotein. Studies in normolipidaemic and hypercholesterolaemic subjects. <i>European Journal of Clinical Investigation</i> , 1992, 22, 383-390.	1.7	13
39	Plasma triglyceride and low density lipoprotein metabolism. <i>European Journal of Clinical Investigation</i> , 1992, 22, 96-104.	1.7	41
40	Genotype at a major locus with large effects on apolipoprotein B levels predicts familial combined hyperlipidemia. <i>Genetic Epidemiology</i> , 1993, 10, 257-270.	0.6	23
41	Lipoprotein subclasses in genetic studies: The Berkeley data set. <i>Genetic Epidemiology</i> , 1993, 10, 523-528.	0.6	5
42	Complex segregation analysis of LDL peak particle diameter. <i>Genetic Epidemiology</i> , 1993, 10, 599-604.	0.6	32
43	Genotype by sex interaction in measures of lipids, lipoproteins, and apolipoproteins. <i>Genetic Epidemiology</i> , 1993, 10, 611-616.	0.6	17
44	Response of plasma low density lipoprotein subfractions to oestrogen replacement therapy following surgical menopause. <i>Clinical Endocrinology</i> , 1993, 39, 463-468.	1.2	44
45	The case for metabolic hypertension: Is it time to restructure the hypertension paradigm?. <i>Progress in Cardiovascular Diseases</i> , 1993, 36, 1-38.	1.6	20
46	Acute and delayed effects of prolonged exercise on serum lipoproteins. <i>European Journal of Applied Physiology and Occupational Physiology</i> , 1993, 66, 526-530.	1.2	24
47	Rationale and design of the Department of Veterans Affairs high-density lipoprotein cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. <i>American Journal of Cardiology</i> , 1993, 71, 45-52.	0.7	108
48	Host and environmental effects on plasma apolipoprotein B. <i>International Journal of Clinical and Laboratory Research</i> , 1993, 23, 215-220.	1.0	7
49	Ultrasound-monitored laser angioplasty: Preliminary clinical results. <i>CardioVascular and Interventional Radiology</i> , 1993, 16, 89-92.	0.9	6
50	Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 1461-1467.	1.5	148
51	Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 1153-1158.	1.5	78
52	Susceptibility of low-density lipoprotein to oxidative modification. <i>American Journal of Medicine</i> , 1993, 94, 347-349.	0.6	51
53	Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. <i>American Journal of Medicine</i> , 1993, 94, 350-356.	0.6	509
54	Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. <i>Atherosclerosis</i> , 1993, 102, 107-119.	0.4	64
55	Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease. <i>Atherosclerosis</i> , 1993, 101, 1-8.	0.4	36

#	ARTICLE	IF	CITATIONS
56	Relationship between apolipoprotein E and low density lipoprotein particle size. <i>Atherosclerosis</i> , 1993, 102, 147-154.	0.4	28
57	Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. <i>Atherosclerosis</i> , 1993, 104, 159-171.	0.4	74
58	Composition of human low density lipoprotein: Effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein. <i>Atherosclerosis</i> , 1993, 98, 33-49.	0.4	124
59	Association of early-onset coronary heart disease in South Asian men with glucose intolerance and hyperinsulinemia.. <i>Circulation</i> , 1993, 87, 152-161.	1.6	321
60	Effects of milk fat, unhydrogenated and partially hydrogenated vegetable oils on serum lipoproteins in growing pigs. <i>Comparative Biochemistry and Physiology A, Comparative Physiology</i> , 1993, 106, 565-570.	0.7	2
61	Dyslipoproteinaemia: an overview with special reference to familial hypercholesterolaemia. <i>Transfusion Science</i> , 1993, 14, 223-237.	0.6	1
62	Dissent What is truth said Pontius Pilate and would not wait for an answer: A biological reply to Dr Stehbens. <i>Journal of Clinical Epidemiology</i> , 1993, 46, 1351-1357.	2.4	1
63	Hypertriglyceridaemia and vascular risk. <i>Lancet, The</i> , 1993, 342, 781-787.	6.3	45
64	Effects of Gemfibrozil on Low-Density Lipoprotein Particle Size, Density Distribution, and Composition in Patients With Type II Diabetes. <i>Diabetes Care</i> , 1993, 16, 584-592.	4.3	78
65	Increased production rates of LDL are common in individuals with low plasma levels of HDL cholesterol, independent of plasma triglyceride concentrations.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1993, 13, 842-851.	3.8	17
66	Dietary fat saturation modifies the metabolism of LDL subfractions in guinea pigs.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1993, 13, 1418-1428.	3.8	37
67	Genetics of LDL subclass phenotypes in women twins. Concordance, heritability, and commingling analysis.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1993, 13, 687-695.	3.8	75
68	Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1993, 13, 427-434.	3.8	86
69	The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 76, 1423-1427.	1.8	153
70	Effects of Diet and Physical Activity on Adiposity and Body Fat Distribution: Implications for the Prevention of Cardiovascular Disease. <i>Nutrition Research Reviews</i> , 1993, 6, 137-159.	2.1	250
71	Postprandial Lipoprotein Metabolism. <i>Nutrition Research Reviews</i> , 1993, 6, 161-183.	2.1	45
72	Effects of Gemfibrozil on Triglyceride Levels in Patients With NIDDM: Hyperlipidemia in Diabetes Investigators. <i>Diabetes Care</i> , 1993, 16, 37-44.	4.3	26
73	Calculated Low-Density Lipoprotein Cholesterol Should Not Be Used for Management of Lipoprotein Abnormalities in Patients With Diabetes Mellitus. <i>Diabetes Care</i> , 1993, 16, 1081-1086.	4.3	115

#	ARTICLE	IF	CITATIONS
74	Relation of plasma triglyceride and apoB levels to insulin-mediated suppression of nonesterified fatty acids. Possible explanation for sex differences in lipoprotein pattern.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 1187-1192.	3.8	55
75	LDL subclass phenotypes and the insulin resistance syndrome in women.. Circulation, 1993, 88, 381-387.	1.6	244
76	Radioimmunoassay for a new bone resorption marker and results for pediatric subjects. Clinical Chemistry, 1993, 39, 1745-1747.	1.5	3
77	Low-density lipoprotein particle size in familial hypercholesterolemia. Clinical Chemistry, 1993, 39, 1747-1747.	1.5	0
78	Low-density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men. FASEB Journal, 1994, 8, 121-126.	0.2	181
79	Particle size: the key to the atherogenic lipoprotein?. QJM - Monthly Journal of the Association of Physicians, 1994, 87, 709-720.	0.2	40
80	Low-Density Lipoprotein Density and Atherosclerosis. JAMA - Journal of the American Medical Association, 1994, 272, 305.	3.8	54
81	Coronary Artery Disease Risk Factors From a Genetic and Developmental Perspective. Archives of Internal Medicine, 1994, 154, 633.	4.3	7
82	Atherogenicity of Triglyceride-Rich Lipoproteins. European Journal of Cardiovascular Prevention and Rehabilitation, 1994, 1, 202-206.	3.1	2
83	Relations of plasma TG and HDL-C concentrations to body composition and plasma insulin levels are altered in men with small LDL particles.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 1121-1128.	3.8	42
84	Genetic predictors of FCHL in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 1687-1694.	3.8	71
85	Determinants of LDL subfraction distribution and concentrations in young normolipidemic subjects.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 902-910.	3.8	110
86	Dyslipidemia in Non-Insulin-Dependent Diabetes Mellitus. Endocrine Reviews, 1994, 15, 263-274.	8.9	56
87	Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management.. Circulation, 1994, 90, 1056-1069.	1.6	166
88	High-Density Lipoproteins and Coronary Heart Disease. European Journal of Cardiovascular Prevention and Rehabilitation, 1994, 1, 217-221.	3.1	9
89	Apolipoprotein B and a second major gene locus contribute to phenotypic variation of spontaneous hypercholesterolemia in pigs.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 409-419.	3.8	4
90	Biological Importance of Low-Density-Lipoprotein Subfractions. European Journal of Cardiovascular Prevention and Rehabilitation, 1994, 1, 207-211.	3.1	7
91	Conjoint high triglycerides and low HDL cholesterol across generations. Analysis of proband hypertriglyceridemia and lipid/lipoprotein disorders in first-degree family members.. Circulation, 1994, 90, 1177-1184.	1.6	17

#	ARTICLE	IF	CITATIONS
92	Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis.. <i>Circulation</i> , 1994, 90, 2230-2235.	1.6	122
93	Small, dense low-density lipoprotein as a risk factor for coronary heart disease. <i>International Journal of Clinical and Laboratory Research</i> , 1994, 24, 187-192.	1.0	45
94	LDL subclasses in IDDM patients: relation to diabetic nephropathy. <i>Diabetologia</i> , 1994, 37, 681-688.	2.9	41
95	Dyslipidemia and coronary artery disease. <i>Clinical Cardiology</i> , 1994, 17, 519-527.	0.7	12
96	Insulin and lipoprotein metabolism with special reference to the diabetic state. <i>Diabetes/metabolism Reviews</i> , 1994, 10, 225-252.	0.2	19
97	The potential social impact of predictive genetic testing for susceptibility to common chronic diseases: a review and proposed research agenda.. <i>Sociology of Health and Illness</i> , 1994, 16, 340-371.	1.1	80
98	Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides*. <i>European Journal of Clinical Investigation</i> , 1994, 24, 669-678.	1.7	43
99	Low-intensity endurance exercise training, plasma lipoproteins and the risk of coronary heart disease. <i>Journal of Internal Medicine</i> , 1994, 236, 7-22.	2.7	135
100	Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil. <i>American Journal of Medicine</i> , 1994, 96, 49-56.	0.6	14
101	Hypertriglyceridemia during late pregnancy is associated with the formation of small dense low-density lipoproteins and the presence of large buoyant high-density lipoproteins. <i>Metabolism: Clinical and Experimental</i> , 1994, 43, 1035-1041.	1.5	76
102	Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. <i>Atherosclerosis</i> , 1994, 110, 1-11.	0.4	46
103	Influence of lipoprotein lipids, dietary fat and smoking on macrophage degradation of native and oxidized low density lipoprotein. <i>Atherosclerosis</i> , 1994, 110, 13-23.	0.4	9
104	Postprandial lipoproteins and progression of coronary atherosclerosis. <i>Atherosclerosis</i> , 1994, 106, 83-97.	0.4	472
105	Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. <i>Atherosclerosis</i> , 1994, 106, 241-253.	0.4	506
106	Familial lipoprotein disorders and premature coronary artery disease. <i>Atherosclerosis</i> , 1994, 108, S41-S54.	0.4	51
107	Oxidation of low density lipoprotein in patients on regular haemodialysis. <i>Atherosclerosis</i> , 1994, 110, 185-193.	0.4	48
108	Effect of pravastatin in the prevention of coronary heart disease in patients with primary hypercholesterolemia. <i>Current Therapeutic Research</i> , 1994, 55, 914-924.	0.5	2
109	Diabetes mellitus – A priority health care issue for women. <i>Journal of the American Dietetic Association</i> , 1994, 94, 976-985.	1.3	17

#	ARTICLE	IF	CITATIONS
110	7 Dyslipidaemia and obesity. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1994, 8, 629-660.	1.0	173
111	The role of oxidation and glycation in the pathogenesis of diabetic atherosclerosis. <i>Trends in Endocrinology and Metabolism</i> , 1994, 5, 329-334.	3.1	17
112	Combined Treatment with Pravastatin and Gemfibrozil in Patients with Refractory Familial Combined Hyperlipidaemia. <i>Drug Investigation</i> , 1994, 7, 134-142.	0.6	13
113	Physical Activity and Lipoprotein Lipid Disorders. <i>Sports Medicine</i> , 1994, 17, 6-21.	3.1	65
114	Familial lipoprotein disorders and premature coronary artery disease. <i>Medical Clinics of North America</i> , 1994, 78, 21-39.	1.1	18
115	The biology of the artery wall in atherogenesis. <i>Medical Clinics of North America</i> , 1994, 78, 41-67.	1.1	40
116	Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein(a) as risk factors for coronary heart disease. <i>Medical Clinics of North America</i> , 1994, 78, 99-115.	1.1	63
117	The Prevalence of Insulin Resistance in Kidney Disease Patients before the Development of Renal Failure. <i>Nephron</i> , 1995, 69, 281-285.	0.9	34
118	Low density lipoproteins and atherosclerosis—quantity or quality?. <i>Redox Report</i> , 1995, 1, 171-176.	1.4	6
119	Rationale for Cholesterol-lowering Strategies. <i>Current Problems in Cardiology</i> , 1995, 20, 286-357.	1.1	1
120	Androgen and progestagen effects on plasma lipids. <i>Progress in Cardiovascular Diseases</i> , 1995, 38, 255-271.	1.6	96
121	Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec) <a href="#">Tj ETQq1 1 0.784314,rgBT /Ov</a>	0.7	149
122	The fourth Musketeer — from Alexandre Dumas to Claude Bernard. <i>Diabetologia</i> , 1995, 38, 3-13.	2.9	212
123	Changes of lipolytic enzymes cluster with insulin resistance syndrome. <i>Diabetologia</i> , 1995, 38, 344-350.	2.9	81
124	New targets for lipid lowering and atherosclerosis prevention. , 1995, 67, 433-447.		6
125	Atherogenic dyslipidemia: Lipoprotein abnormalities and implications for therapy. <i>American Journal of Cardiology</i> , 1995, 75, 45B-52B.	0.7	53
126	Dense low density lipoproteins and coronary artery disease. <i>American Journal of Cardiology</i> , 1995, 75, 53B-57B.	0.7	132
127	Clinical significance of lipoprotein size and risk for coronary atherosclerosis. <i>Clinical Chemistry</i> , 1995, 41, 147-152.	1.5	45

#	ARTICLE	IF	CITATIONS
128	LDL Physical and Chemical Properties in Familial Combined Hyperlipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 452-459.	1.1	62
129	Effect of Diabetes on Lipoprotein Size. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 1805-1811.	1.1	65
130	Association of Postprandial Triglyceride and Retinyl Palmitate Responses With Newly Diagnosed Exercise-Induced Myocardial Ischemia in Middle-Aged Men and Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 1829-1838.	1.1	120
131	Relations Between Plasma Lipids and Postheparin Plasma Lipases and VLDL and LDL Subfraction Patterns in Normolipemic Men and Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 1839-1848.	1.1	116
132	A Common Variant in the Gene for Lipoprotein Lipase (Asp9â†’Asn). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 468-478.	1.1	143
133	Lipid Parameters Including Lipoprotein (A) in Patients Undergoing CAPD and Hemodialysis. <i>Peritoneal Dialysis International</i> , 1995, 15, 342-347.	1.1	60
134	Persistence of Low HDL-C Levels After Weight Reduction in Older Men With Small LDL Particles. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 299-305.	1.1	26
135	The Response-to-Retention Hypothesis of Early Atherogenesis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 551-561.	1.1	1,202
136	Low-density-lipoprotein subclasses and response to a low-fat diet in healthy men. <i>American Journal of Clinical Nutrition</i> , 1995, 62, 478S-487S.	2.2	131
137	Management of Primary Hyperlipidemia. <i>New England Journal of Medicine</i> , 1995, 332, 1491-1498.	13.9	178
138	Relationship of Low-Density Lipoprotein Particle Size to Plasma Lipoproteins, Obesity, and Insulin Resistance in Japanese Men. <i>Diabetes Care</i> , 1995, 18, 333-338.	4.3	27
139	Serum Total Cholesterol and Long-term Coronary Heart Disease Mortality in Different Cultures. <i>JAMA - Journal of the American Medical Association</i> , 1995, 274, 131.	3.8	503
140	High-Density Lipoprotein Cholesterol, Plasma Triglyceride, and Coronary Heart Disease: Pathophysiology and Management. <i>Advances in Pharmacology</i> , 1995, 32, 375-426.	1.2	27
141	Insights Into the Pathogenesis and Prevention of Coronary Artery Disease. <i>Mayo Clinic Proceedings</i> , 1995, 70, 69-79.	1.4	40
142	Influence of Dietary Fatty Acids on the Atherogenic Lipoprotein Phenotype. <i>Nutrition Research Reviews</i> , 1995, 8, 1-26.	2.1	31
144	Physico-Chemical Properties of Low Density Lipoproteins in Normolipidemic Asian Indian Men. <i>Hormone and Metabolic Research</i> , 1995, 27, 326-331.	0.7	11
145	Plasma cholesterol esterase level is a determinant for an atherogenic lipoprotein profile in normolipidemic human subjects. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1995, 1272, 69-72.	1.8	69
146	Relationship between obesity and concentration and composition of low-density lipoprotein subfractions in normoinsulinemic men. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 1384-1390.	1.5	26

#	ARTICLE	IF	CITATIONS
147	Association of insulin and insulin propeptides with an atherogenic lipoprotein phenotype. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 1481-1488.	1.5	16
148	Compositions of very low density lipoprotein subfractions from patients with polydisperse low density lipoproteins. <i>Clinica Chimica Acta</i> , 1995, 238, 43-57.	0.5	5
149	The total apolipoprotein B/LDL-cholesterol ratio does not predict LDL particle size. <i>Clinica Chimica Acta</i> , 1995, 240, 63-73.	0.5	10
150	Enhanced susceptibility of low-density lipoproteins to oxidation in coronary bypass patients with progression of atherosclerosis. <i>Clinica Chimica Acta</i> , 1995, 243, 137-149.	0.5	28
151	Effects of gemfibrozil on plasma lipoproteins, plasma activities of hepatic enzymes, and hemostatic variables in hypertriglyceridemic patients. <i>Current Therapeutic Research</i> , 1995, 56, 597-606.	0.5	2
152	Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridemic patients. <i>Atherosclerosis</i> , 1995, 113, 1-9.	0.4	31
153	LDL particle size in mildly hypertriglyceridemic subjects: no relation to insulin resistance or diabetes. <i>Atherosclerosis</i> , 1995, 113, 227-236.	0.4	39
154	Treatment of primary mixed hyperlipidemia with etophylline clofibrate: effects on lipoprotein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition. <i>Atherosclerosis</i> , 1995, 117, 253-261.	0.4	8
155	Abnormal cholesterol distribution among lipoprotein fractions in normolipidemic patients with mild NIDDM. <i>Atherosclerosis</i> , 1995, 118, 111-122.	0.4	30
156	Low-density lipoprotein heterogeneity. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1995, 9, 687-703.	1.0	20
157	Lipoproteins and the progression/regression of atherosclerosis. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1995, 9, 849-866.	1.0	11
158	Insights Into the Pathogenesis and Prevention of Coronary Artery Disease. <i>Mayo Clinic Proceedings</i> , 1995, 70, 69-79.	1.4	35
159	Intra-abdominal fat: is it a major factor in developing diabetes and coronary artery disease?. <i>Diabetes Research and Clinical Practice</i> , 1996, 30, S25-S30.	1.1	87
160	Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1996, 3, 213-219.	3.1	604
161	Dyslipidemia in diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 1996, 33, 1-14.	1.1	48
162	The effect of physical activity on serum total and low-density lipoprotein cholesterol concentrations varies with apolipoprotein E phenotype in male children and young adults: The cardiovascular risk in young finns study. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 797-803.	1.5	62
163	Women have a larger and less atherogenic low density lipoprotein particle size than men. <i>Atherosclerosis</i> , 1996, 119, 181-190.	0.4	52
164	Prevalence of hyperapobetalipoproteinemia and factors affecting the phenotype expression in children and young adults The Cardiovascular Risk in Young Finns Study. <i>Atherosclerosis</i> , 1996, 122, 79-88.	0.4	1

#	ARTICLE	IF	CITATIONS
165	High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy. <i>Atherosclerosis</i> , 1996, 123, 57-72.	0.4	38
166	Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. <i>Atherosclerosis</i> , 1996, 124, 261-271.	0.4	215
167	Lipids, risk factors and ischaemic heart disease. <i>Atherosclerosis</i> , 1996, 124, S1-S9.	0.4	293
168	LDL particle size in subjects with previously unsuspected coronary heart disease: relationship with other cardiovascular risk markers. <i>Atherosclerosis</i> , 1996, 126, 277-287.	0.4	25
169	Triglyceride expression. <i>International Journal of Cardiology</i> , 1996, 57, 167-171.	0.8	0
170	[2] Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. <i>Methods in Enzymology</i> , 1996, 263, 32-60.	0.4	88
171	Pilot Study of the Effect of the Simvastatin-Ciprofibrate Combination on Myocardial Infarction Risk Profile in Patients with Refractory Familial Combined Hyperlipidaemia. <i>Clinical Drug Investigation</i> , 1996, 11, 196-204.	1.1	1
172	Direct measurement of LDL cholesterol. <i>Clinical Chemistry</i> , 1996, 42, 780-781.	1.5	6
173	Lipoprotein Subclasses in the Monitored Atherosclerosis Regression Study (MARS). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 697-704.	1.1	168
174	Association Between Serum Fibrinogen Concentrations and HDL and LDL Subfraction Phenotypes in Healthy Men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 144-148.	1.1	35
176	Analysis of Apolipoproteins. <i>Annals of Clinical Biochemistry</i> , 1996, 33, 5-22.	0.8	8
177	[1] Apolipoproteins: Pathophysiology and clinical implications. <i>Methods in Enzymology</i> , 1996, 263, 3-32.	0.4	12
178	Prevention and Regression of Atherosclerosis: Effects of Hmg-CoA Reductase Inhibitors. <i>Annals of Pharmacotherapy</i> , 1996, 30, 1304-1315.	0.9	4
179	Lipid disorders contributing to coronary heart disease: An update. <i>Current Problems in Cardiology</i> , 1996, 21, 733-780.	1.1	5
180	Hypertriglyceridemia and its Metabolic Consequences as a Risk Factor for Atherosclerotic Cardiovascular Disease in Non-Insulin-Dependent Diabetes Mellitus. <i>Diabetes/metabolism Reviews</i> , 1996, 12, 37-56.	0.2	65
181	Lipoprotein metabolism in non-insulin-dependent diabetes mellitus. <i>Journal of Nutritional Biochemistry</i> , 1996, 7, 586-598.	1.9	10
182	Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. <i>European Journal of Clinical Investigation</i> , 1996, 26, 89-108.	1.7	109
183	Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. <i>Diabetologia</i> , 1996, 39, 453-461.	2.9	103

#	ARTICLE	IF	CITATIONS
184	The ApoB-100 Gene <i>Eco</i> RI Polymorphism Influences the Relationship Between Features of the Insulin Resistance Syndrome and the Hyper-ApoB and Dense LDL Phenotype in Men. <i>Diabetes</i> , 1996, 45, 1405-1411.	0.3	18
185	Association of Small Low-Density Lipoprotein Particles With the Incidence of Coronary Artery Disease in Men and Women. <i>JAMA - Journal of the American Medical Association</i> , 1996, 276, 875.	3.8	597
186	The Dense LDL Phenotype: Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. <i>Diabetes Care</i> , 1996, 19, 629-637.	4.3	276
187	Genetic Epidemiology of Dyslipidaemia and Atherosclerosis. <i>Annals of Medicine</i> , 1996, 28, 459-463.	1.5	10
188	Criteria for Metabolic Control and Intervention in Diabetes. <i>Diabetes</i> , 1996, 45, S120-S122.	0.3	11
189	New Insights into Lipid Metabolism in Non-insulin-dependent Diabetes Mellitus. <i>Annals of Medicine</i> , 1996, 28, 335-340.	1.5	47
190	Lipids and Stroke. <i>Archives of Neurology</i> , 1996, 53, 303.	4.9	141
191	Secondary Prevention of Coronary Heart Disease in Patients with Extracoronary Atherosclerosis: A Need for Accuracy of Low Density Lipoprotein Determination. <i>Angiology</i> , 1996, 47, 241-246.	0.8	5
192	When to treat dyslipidaemia of patients with chronic renal failure on haemodialysis? A need to define specific guidelines. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 308-313.	0.4	16
194	Lipoprotein Subfraction Changes in Normal Pregnancy: Threshold Effect of Plasma Triglyceride on Appearance of Small, Dense Low Density Lipoprotein1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 2483-2491.	1.8	154
195	Optimization of Glycemic Control by Insulin Therapy Decreases the Proportion of Small Dense LDL Particles in Diabetic Patients. <i>Diabetes</i> , 1997, 46, 1207-1213.	0.3	70
196	Simplified Sizing of Low-Density Lipoprotein Using Polyacrylamide Gradient Gel Electrophoresis of Plasma. <i>Clinical Chemistry and Laboratory Medicine</i> , 1997, 35, 17-9.	1.4	1
197	Fat as a Fuel for Exercise. , 1997, 82, 46-62.		3
198	Lipids, thrombosis and cardiovascular disease in diabetes. <i>Proceedings of the Nutrition Society</i> , 1997, 56, 273-280.	0.4	1
199	Cardiovascular risk factors in women. <i>Proceedings of the Nutrition Society</i> , 1997, 56, 383-391.	0.4	26
200	Triacylglycerol and coronary heart disease. <i>Proceedings of the Nutrition Society</i> , 1997, 56, 667-670.	0.4	37
201	Preserved Antilipolytic Insulin Action Is Associated with a Less Atherogenic Plasma Lipid Profile in Healthy Centenarians. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 1504-1509.	1.3	18
202	Diet-gene interactions in human lipoprotein metabolism.. <i>Journal of the American College of Nutrition</i> , 1997, 16, 313-324.	1.1	49

#	ARTICLE	IF	CITATIONS
203	PHYSIOLOGIC CONSEQUENCES OF TRAINING. <i>Cardiology Clinics</i> , 1997, 15, 345-354.	0.9	28
204	Lipids and Lipoproteins in Women. <i>Mayo Clinic Proceedings</i> , 1997, 72, 235-244.	1.4	45
205	Relationship of serum ferritin concentrations with metabolic cardiovascular risk factors in men without evidence for coronary artery disease. <i>Atherosclerosis</i> , 1997, 128, 235-240.	0.4	67
206	LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I. <i>Atherosclerosis</i> , 1997, 129, 59-65.	0.4	48
207	Influence of apo E phenotype on postprandial triglyceride and glucose responses in subjects with and without coronary heart disease. <i>Atherosclerosis</i> , 1997, 130, 161-170.	0.4	32
208	Evidence-Based Performance and Outcome Measures for Diabetes Care. <i>Disease Management and Health Outcomes</i> , 1997, 2, 124-133.	0.3	4
209	The effects of exercise on primary and secondary coronary heart disease. <i>Coronary Health Care</i> , 1997, 1, 60-78.	0.4	1
210	Remnant-like very-low-density lipoprotein isolated from hypertriglyceridemic patients by immunoaffinity chromatography suppressed 3-hydroxy-3-methylglutaryl coenzyme A activity of cultured human skin fibroblasts. <i>Clinica Chimica Acta</i> , 1997, 258, 145-158.	0.5	7
211	Interaction of family history of atherosclerosis with atherogenic lipid traits in men with non-coronary atherosclerosis. <i>Clinica Chimica Acta</i> , 1997, 264, 193-205.	0.5	0
212	Effects of dietary fat restriction on particle size of plasma lipoproteins in postmenopausal women. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 431-436.	1.5	18
213	Low-density lipoprotein particle size is not a discriminating marker for atherogenic risk in male offspring of parents with early coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 954-958.	1.5	11
214	Characterization of low-density lipoprotein subclasses in children. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 146-148.	1.5	24
215	Differences in the concentration and composition of low-density lipoprotein subfraction particles between sedentary and trained hypercholesterolemic men. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 186-191.	1.5	34
216	Lipid abnormalities in Greek patients with coronary artery disease. <i>International Journal of Cardiology</i> , 1997, 59, 177-184.	0.8	11
217	Oligonucleotide Ligation Assay for Detection of Apolipoprotein E Polymorphisms. <i>Clinical Chemistry</i> , 1997, 43, 1984-1986.	1.5	13
218	Measurement of Na <sup>+</sup> /K <sup>+</sup> -ATPase Activity with an Automated Analyzer. <i>Clinical Chemistry</i> , 1997, 43, 1986-1987.	1.5	13
219	Genetic, Metabolic, and Dietary Influences on the Atherogenic Lipoprotein Phenotype. , 1997, 80, 22-43.		18
220	Interaction of Very-Low-Density, Intermediate-Density, and Low-Density Lipoproteins With Human Arterial Wall Proteoglycans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2507-2514.	1.1	102

#	ARTICLE	IF	CITATIONS
221	Vitamin E/Lipid Peroxide Ratio and Susceptibility of LDL to Oxidative Modification in Non-Insulin-Dependent Diabetes Mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 1438-1446.	1.1	47
222	Lipoprotein Heterogeneity and Apolipoprotein B Metabolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 3542-3556.	1.1	352
223	Relation of LDL Size to the Insulin Resistance Syndrome and Coronary Heart Disease in American Indians. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2713-2720.	1.1	89
224	Monounsaturated and Marine $\omega$ -3 Fatty Acids in NIDDM Patients. <i>Annals of the New York Academy of Sciences</i> , 1997, 827, 302-309.	1.8	9
225	Low-density lipoprotein and oxidised low-density lipoprotein: Their role in the development of atherosclerosis. , 1997, 74, 55-72.		57
226	LDL heterogeneity: implications for atherogenicity in insulin resistance and NIDDM. <i>Diabetologia</i> , 1997, 40, S149-S151.	2.9	11
227	Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low-density lipoprotein heterogeneity. <i>European Journal of Clinical Investigation</i> , 1997, 27, 802-811.	1.7	34
228	Analytical capillary isotachopheresis of human serum lipoproteins. <i>Electrophoresis</i> , 1997, 18, 1807-1813.	1.3	94
230	Associations of indices of adiposity with atherogenic lipoprotein subfractions. <i>International Journal of Obesity</i> , 1998, 22, 432-439.	1.6	86
231	Hypertriglyceridemia as a Cardiovascular Risk Factor. <i>American Journal of Cardiology</i> , 1998, 81, 7B-12B.	0.7	906
232	Atherogenicity of Triglyceride-Rich Lipoproteins. <i>American Journal of Cardiology</i> , 1998, 81, 13B-17B.	0.7	193
233	Hypertriglyceridemia, Atherogenic Dyslipidemia, and the Metabolic Syndrome. <i>American Journal of Cardiology</i> , 1998, 81, 18B-25B.	0.7	451
234	Treatment strategies for management of serum lipids: Lessons learned from lipid metabolism, recent clinical trials, and experience with the HMG CoA reductase inhibitors. <i>Progress in Cardiovascular Diseases</i> , 1998, 41, 95-116.	1.6	14
235	Lipid-Lowering Drugs in the Management of Hyperlipidaemia. , 1998, 79, 205-230.		63
236	Lipoprotein disorder in brain infarction and hemorrhage. <i>International Journal of Clinical and Laboratory Research</i> , 1998, 28, 39-46.	1.0	8
237	Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage. <i>European Journal of Clinical Pharmacology</i> , 1998, 54, 697-699.	0.8	10
238	Risk factors for mortality in Type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. <i>Diabetologia</i> , 1998, 41, 1253-1262.	2.9	115
239	Hypertriglyceridemia and insulin resistance. <i>Journal of Internal Medicine</i> , 1998, 243, 79-82.	2.7	13

#	ARTICLE	IF	CITATIONS
240	Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia. <i>British Journal of Clinical Pharmacology</i> , 1998, 45, 265-269.	1.1	12
241	Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 1097-1104.	1.5	222
242	VLDL compositional changes and plasma levels of triglycerides and high density lipoprotein. <i>Clinica Chimica Acta</i> , 1998, 269, 107-124.	0.5	22
243	Incidence of lipoprotein lipase genotype for premature termination codon (Ser447-Ter) in Japanese, and association with dyslipoproteinemia. <i>Clinica Chimica Acta</i> , 1998, 275, 205-213.	0.5	8
244	Modulation of LDL particle size after an oral glucose load is associated with insulin levels. <i>Clinica Chimica Acta</i> , 1998, 276, 143-155.	0.5	8
245	Aggressive medical therapy for the prevention and treatment of coronary artery disease. <i>Disease-a-Month</i> , 1998, 44, 1-40.	0.4	1
246	Normal Triglyceride Levels and Coronary Artery Disease Events: The Baltimore Coronary Observational Long-Term Study 11This study was supported by Grants HL02263 and HL52663 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.. <i>Journal of the American College of Cardiology</i> , 1998, 31, 1252-1257.	1.2	175
247	Candidate-Gene Studies of the Atherogenic Lipoprotein Phenotype: A Sib-Pair Linkage Analysis of DZ Women Twins. <i>American Journal of Human Genetics</i> , 1998, 62, 406-419.	2.6	67
248	Families with Familial Combined Hyperlipidemia and Families Enriched for Coronary Artery Disease Share Genetic Determinants for the Atherogenic Lipoprotein Phenotype. <i>American Journal of Human Genetics</i> , 1998, 63, 577-585.	2.6	58
249	VASCULAR DISEASE AND LIPIDS IN DIABETES. <i>Medical Clinics of North America</i> , 1998, 82, 931-948.	1.1	40
250	GENETICS OF LIPOPROTEIN DISORDERS. <i>Endocrinology and Metabolism Clinics of North America</i> , 1998, 27, 521-550.	1.2	28
251	Visceral obesity and the risk of ischaemic heart disease: insights from the Québec Cardiovascular Study. <i>Growth Hormone and IGF Research</i> , 1998, 8, 1-8.	0.5	44
252	Biologic markers as predictors of cardiovascular disease. <i>American Journal of Medicine</i> , 1998, 104, 18S-27S.	0.6	102
253	Effect of infusion of a triacylglycerol emulsion on low-density lipoprotein composition and oxidizability. <i>Atherosclerosis</i> , 1998, 137, 115-123.	0.4	9
254	Evidence based approach for the management of mixed hyperlipidaemia. <i>Atherosclerosis</i> , 1998, 137, S97-S100.	0.4	10
255	Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study. <i>Atherosclerosis</i> , 1998, 139, 179-187.	0.4	35
256	Association of apo B lipoproteins with arterial proteoglycans: Pathological significance and molecular basis. <i>Atherosclerosis</i> , 1998, 139, 205-222.	0.4	299
257	High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia. <i>Atherosclerosis</i> , 1998, 141, 77-85.	0.4	48

#	ARTICLE	IF	CITATIONS
258	In vitro production of $\hat{1}^2$ -very low density lipoproteins and small, dense low density lipoproteins in mildly hypertriglyceridemic plasma: role of activities of lecithin:cholester acyltransferase, cholesterylester transfer proteins and lipoprotein lipase. <i>Atherosclerosis</i> , 1998, 141, 209-225.	0.4	38
259	The Role of Lipid-Lowering Therapy in Multiple Risk Factor Management. <i>Drugs</i> , 1998, 56, 1-7.	4.9	19
260	Caloric Restriction in Rhesus Monkeys Reduces Low Density Lipoprotein Interaction with Arterial Proteoglycans. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 1998, 53A, B443-B448.	1.7	55
261	The Adipocyte, Fatty Acid Trapping, and Atherogenesis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 147-151.	1.1	123
262	Influence of ApoE Content on Receptor Binding of Large, Buoyant LDL in Subjects With Different LDL Subclass Phenotypes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 466-472.	1.1	8
263	Insulin Resistance and Human Disease: A Short History. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 1998, 9, 387-406.	0.7	51
264	Effect of Excessive Weight Gain With Intensive Therapy of Type 1 Diabetes on Lipid Levels and Blood Pressure. <i>JAMA - Journal of the American Medical Association</i> , 1998, 280, 140.	3.8	395
265	LDL Size Distribution in Relation to Insulin Sensitivity and Lipoprotein Pattern in Young and Healthy Subjects. <i>Diabetes Care</i> , 1998, 21, 2077-2084.	4.3	44
266	Primary Prevention of Coronary Heart Disease: Guidance From Framingham. <i>Circulation</i> , 1998, 97, 1876-1887.	1.6	520
267	The Atherogenic Significance of an Elevated Plasma Triglyceride Level. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 1998, 35, 489-516.	2.7	35
268	Common Variants in the Promoter of the Hepatic Lipase Gene Are Associated With Lower Levels of Hepatic Lipase Activity, Buoyant LDL, and Higher HDL $\times 2$ Cholesterol. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 1723-1729.	1.1	175
269	Diabetes and Long-Term Risk of Mortality From Coronary and Other Causes in Middle-Aged Swedish Men: A general population study. <i>Diabetes Care</i> , 1998, 21, 539-545.	4.3	90
270	Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function. <i>European Heart Journal</i> , 1998, 19, 402-410.	1.0	59
271	Response to Howard and Howard. <i>Diabetes Care</i> , 1998, 21, 2202-2203.	4.3	1
272	Sialic Acid Content of LDL in Coronary Artery Disease: No Evidence of Desialylation in Subjects With Coronary Stenosis and Increased Levels in Subjects With Extensive Atherosclerosis and Acute Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 876-883.	1.1	28
273	Low Density Lipoprotein Particle Size is Associated with Glycosylated Hemoglobin Levels Regardless of Plasma Lipid Levels.. <i>Internal Medicine</i> , 1998, 37, 273-279.	0.3	12
274	Association of atherogenic low-density lipoprotein subfractions with carotid atherosclerosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1998, 91, 345-351.	0.2	52
275	Functional food science and substrate metabolism. <i>British Journal of Nutrition</i> , 1998, 80, S47-S75.	1.2	44

#	ARTICLE	IF	CITATIONS
276	Exercise and postprandial lipid metabolism. Proceedings of the Nutrition Society, 1998, 57, 63-72.	0.4	14
277	Effect of Intensive Glycemic Control on Fibrinogen, Lipids, and Lipoproteins. Archives of Internal Medicine, 1998, 158, 2485.	4.3	58
278	Effect of fish-oil-enriched margarine on plasma lipids, low-density-lipoprotein particle composition, size, and susceptibility to oxidation. American Journal of Clinical Nutrition, 1998, 68, 235-241.	2.2	82
279	Low-Density Lipoprotein Particle Size Distribution in Subjects with Coronary Artery Disease. Sunhwan'gi, 1998, 28, 1253.	0.3	1
280	Postprandial lipemia in endurance-trained people during a short interruption to training. Journal of Applied Physiology, 1998, 84, 1895-1901.	1.2	95
281	The Association of Hypertension and Dyslipidemia in Postmenopausal Women. Sunhwan'gi, 1999, 29, 1195.	0.3	2
282	The Role of Dietary Fat in Child Nutrition and Development: Summary of an ASNS Workshop. Journal of Nutrition, 1999, 129, 2094-2105.	1.3	39
283	Apolipoprotein B 5â€™-Ins/Del and 3â€™-VNTR Polymorphisms in Chinese, Malay and Indian Singaporeans. Human Heredity, 1999, 49, 31-40.	0.4	17
284	Correction of Hyperandrogenemia by Laparoscopic Ovarian Cautery in Women with Polycystic Ovarian Syndrome Is Not Accompanied by Improved Insulin Sensitivity or Lipid-Lipoprotein Levels1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4278-4282.	1.8	49
285	Association of Physical Fitness With LDL and HDL Subfractions in Young Healthy Men. International Journal of Sports Medicine, 1999, 20, 464-469.	0.8	25
286	A Hepatic Lipase Gene Promoter Polymorphism Attenuates the Increase in Hepatic Lipase Activity With Increasing Intra-abdominal Fat in Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2701-2707.	1.1	68
287	A Genome Search Identifies Major Quantitative Trait Loci on Human Chromosomes 3 and 4 That Influence Cholesterol Concentrations in Small LDL Particles. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 777-783.	1.1	84
288	Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes. Diabetes Care, 1999, 22, 1165-1170.	4.3	52
289	Pleiotropic Genetic Effects on LDL Size, Plasma Triglyceride, and HDL Cholesterol in Families. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2456-2464.	1.1	73
290	Evidence for a New Pathophysiological Mechanism for Coronary Artery Disease Regression. Circulation, 1999, 99, 1959-1964.	1.6	250
291	THE OPTIMAL RATIO OF FAT-TO-CARBOHYDRATE IN THE DIET. Annual Review of Nutrition, 1999, 19, 325-341.	4.3	60
292	Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations. Circulation, 1999, 100, 1481-1492.	1.6	991
293	LDL Size in African Americans, Hispanics, and Non-Hispanic Whites. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2234-2240.	1.1	87

#	ARTICLE	IF	CITATIONS
294	Diabetic retinopathy. Outcome at five-year follow-up of 203 people with diabetes. 2: Analysis. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 1999, 16, 68-70.	0.2	2
295	Diabetic dyslipidaemia. European Journal of Clinical Investigation, 1999, 29, 12-16.	1.7	41
296	Insulin resistance and familial dyslipidaemias. Diabetes, Obesity and Metabolism, 1999, 1, 323-330.	2.2	7
297	The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylureas in patients with Type 2 diabetes mellitus. Diabetic Medicine, 1999, 16, 820-826.	1.2	12
298	Effects of hypocaloric dietary treatment enriched in oleic acid on LDL and HDL subclass distribution in mildly obese women. Journal of Internal Medicine, 1999, 246, 191-201.	2.7	27
299	The quantitation of lipoprotein lipase mRNA in biopsies of human adipose tissue, using the polymerase chain reaction, and the effect of increased consumption of n-3 polyunsaturated fatty acids. European Journal of Clinical Nutrition, 1999, 53, 441-447.	1.3	10
300	Relationship of low-density lipoprotein particle size and measures of adiposity. International Journal of Obesity, 1999, 23, 180-189.	1.6	56
301	The effect of moxonidine on plasma lipid profile and on LDL subclass distribution. Journal of Human Hypertension, 1999, 13, 781-785.	1.0	13
302	Application of electrophoretic techniques to the diagnosis of disorders of lipoprotein metabolism. Examples at the levels of lipoproteins and apolipoproteins. Analytica Chimica Acta, 1999, 383, 169-184.	2.6	8
303	The epidemiology of triglyceride as a coronary artery disease risk factor. Clinical Cardiology, 1999, 22, II-1-II-6.	0.7	29
304	Long-chain n-3 polyunsaturated fatty acids and triacylglycerol metabolism in the postprandial state. Lipids, 1999, 34, S259-S265.	0.7	60
305	Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. American Journal of Cardiology, 1999, 83, 3-12.	0.7	410
306	Insulin resistance and lipid metabolism. American Journal of Cardiology, 1999, 84, 28-32.	0.7	187
307	Cardiovascular disease: Pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke. American Journal of Obstetrics and Gynecology, 1999, 180, S349-S356.	0.7	37
308	Postprandial Low-Density Lipoproteins in Type 2 Diabetes are Oxidized More Extensively Than Fasting Diabetes and Control Samples. Proceedings of the Society for Experimental Biology and Medicine, 1999, 222, 178-184.	2.0	56
309	Inheritance of LDL peak particle diameter: Results from a segregation analysis in Israeli families. , 1999, 16, 382-396.		12
310	Atherogenic lipoprotein phenotype in Type 2 diabetes: reversal with micronised fenofibrate. Diabetes/Metabolism Research and Reviews, 1999, 15, 395-399.	1.7	64
311	Linkage of Low-Density Lipoprotein Size to the Lipoprotein Lipase Gene in Heterozygous Lipoprotein Lipase Deficiency. American Journal of Human Genetics, 1999, 64, 608-618.	2.6	42

#	ARTICLE	IF	CITATIONS
312	The fatty acid distribution in low density lipoprotein in diabetes. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 1999, 1439, 110-116.	1.2	14
313	The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. <i>Diabetes Research and Clinical Practice</i> , 1999, 46, 35-41.	1.1	62
314	Diabetes and Cardiovascular Disease. <i>Circulation</i> , 1999, 100, 1134-1146.	1.6	1,903
315	Relationship between the apolipoprotein E and angiotensin-converting enzyme genotypes and LDL particle size in Japanese subjects. <i>Clinica Chimica Acta</i> , 1999, 285, 91-103.	0.5	9
316	Prevention of coronary heart disease Part I. Primary prevention. <i>Disease-a-Month</i> , 1999, 45, 497-571.	0.4	8
317	Visceral adipose tissue and low-density lipoprotein particle size in middle-aged versus young men. <i>Metabolism: Clinical and Experimental</i> , 1999, 48, 1322-1327.	1.5	16
318	Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. <i>Journal of the American College of Cardiology</i> , 1999, 34, 1348-1359.	1.2	368
319	Alterations in low-density lipoprotein and high-density lipoprotein subclasses among hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. <i>Fertility and Sterility</i> , 1999, 72, 990-995.	0.5	53
320	Linkage analysis of candidate genes and the small, dense low-density lipoprotein phenotype. <i>Atherosclerosis</i> , 1999, 142, 79-87.	0.4	28
321	Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men. <i>Atherosclerosis</i> , 1999, 142, 113-119.	0.4	61
322	Influence of mild to moderately elevated triglyceride levels on low density lipoprotein subfraction concentration and composition in healthy men with low high density lipoprotein cholesterol levels. <i>Atherosclerosis</i> , 1999, 143, 185-192.	0.4	31
323	Correlation of serum triglyceride and its reduction by n-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. <i>Atherosclerosis</i> , 1999, 143, 285-297.	0.4	161
324	Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. <i>Atherosclerosis</i> , 1999, 146, 187-193.	0.4	39
325	Long-term effects of fish oil on lipoprotein subfractions and low density lipoprotein size in non-insulin-dependent diabetic patients with hypertriglyceridemia. <i>Atherosclerosis</i> , 1999, 146, 361-367.	0.4	30
326	Low density lipoprotein (LDL) binding affinity for the LDL receptor in hyperlipoproteinemia. <i>Atherosclerosis</i> , 1999, 147, 77-86.	0.4	28
327	Low-Density Lipoprotein Size in Primary Hypothyroidism. <i>Annals of Nutrition and Metabolism</i> , 1999, 43, 374-379.	1.0	16
328	Giving Triglycerides Their Due. <i>Hospital Practice (1995)</i> , 1999, 34, 67-73.	0.5	0
329	Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects. <i>Clinical Science</i> , 1999, 97, 269-276.	1.8	22

#	ARTICLE	IF	CITATIONS
330	Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects. <i>Clinical Science</i> , 1999, 97, 269.	1.8	14
331	Dietary carbohydrates and triacylglycerol metabolism. <i>Proceedings of the Nutrition Society</i> , 1999, 58, 201-207.	0.4	33
332	Understanding coronary heart disease as a consequence of defective regulation of apolipoprotein B metabolism. <i>Current Opinion in Lipidology</i> , 1999, 10, 237-244.	1.2	46
333	The Role of Non-High-Density Lipoprotein-Cholesterol in Evaluation and Treatment of Lipid Disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2105-2108.	1.8	2
335	Thiazolidinediones, dyslipidaemia and insulin resistance syndrome. <i>Current Opinion in Lipidology</i> , 2000, 11, 397-402.	1.2	25
336	Therapeutic modulation of low-density lipoprotein size. <i>Current Opinion in Lipidology</i> , 2000, 11, 597-602.	1.2	18
337	Reverse cholesterol transport in diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , 2000, 16, 237-250.	1.7	41
338	Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 263-270.	2.2	4
339	Lipoprotein abnormalities are highly prevalent in pediatric heart transplant recipients. <i>Pediatric Transplantation</i> , 2000, 4, 193-199.	0.5	36
340	Lack of association between lipaemia and central adiposity in subjects with an atherogenic lipoprotein phenotype (ALP). <i>International Journal of Obesity</i> , 2000, 24, 1097-1106.	1.6	12
341	Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. <i>American Journal of Cardiology</i> , 2000, 86, 412-416.	0.7	109
342	The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. <i>American Journal of Cardiology</i> , 2000, 86, 5-10.	0.7	174
343	Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the veterans affairs high-density lipoprotein intervention trial. <i>American Journal of Cardiology</i> , 2000, 86, 23-27.	0.7	44
344	Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. <i>Current Atherosclerosis Reports</i> , 2000, 2, 200-207.	2.0	104
345	Postprandial lipemia and coronary risk. <i>Current Atherosclerosis Reports</i> , 2000, 2, 232-242.	2.0	34
346	Effect of long-chain n-3 polyunsaturated fatty acids on fasting and postprandial triacylglycerol metabolism. <i>American Journal of Clinical Nutrition</i> , 2000, 71, 232S-237S.	2.2	162
347	Hypertriglyceridemia and Coronary Heart Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2098-2105.	1.8	14
348	Reduced LDL particle size in children consuming a very-low-fat diet is related to parental LDL-subclass patterns. <i>American Journal of Clinical Nutrition</i> , 2000, 71, 1611-1616.	2.2	65

#	ARTICLE	IF	CITATIONS
349	Prior exercise and postprandial substrate extraction across the human leg. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2000, 279, E1020-E1028.	1.8	95
350	LDL subfractions in patients with myocardial infarction: effect of smoking and $\beta$ -blocker treatment. <i>Annals of Clinical Biochemistry</i> , 2000, 37, 313-318.	0.8	10
351	“Random Thoughts and Opinions. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2110-2112.	1.8	1
352	The Interface of Genetics and Public Health: Research and Educational Challenges. <i>Annual Review of Public Health</i> , 2000, 21, 81-99.	7.6	21
353	ApoE Polymorphism and Fish Oil Supplementation in Subjects With an Atherogenic Lipoprotein Phenotype. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1990-1997.	1.1	204
354	Antioxidant Vitamin Concentrations and LDL Oxidation in Nephrotic Syndrome. <i>Annals of Clinical Biochemistry</i> , 2000, 37, 488-491.	0.8	8
355	The Insulin Resistance Syndrome: Impact on Lipoprotein Metabolism and Atherothrombosis. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2000, 7, 325-331.	3.1	142
356	Low Density Lipoprotein (LDL) Subfractions during Pregnancy: Accumulation of Buoyant LDL with Advancing Gestation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4543-4550.	1.8	84
357	Effect of Insulin and Sulfonylurea Therapy, at the Same Level of Blood Glucose Control, on Low Density Lipoprotein Subfractions in Type 2 Diabetic Patients1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4188-4192.	1.8	22
358	Primary Prevention of Coronary Heart Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2089-2092.	1.8	63
359	Endothelial Dysfunction in Men With Small LDL Particles. <i>Circulation</i> , 2000, 102, 716-721.	1.6	120
361	Fasting Lipoprotein and Postprandial Triacylglycerol Responses to a Low-Carbohydrate Diet Supplemented with n-3 Fatty Acids. <i>Journal of the American College of Nutrition</i> , 2000, 19, 383-391.	1.1	78
362	Linkage of the Cholesteryl Ester Transfer Protein ( CETP ) Gene to LDL Particle Size. <i>Circulation</i> , 2000, 101, 2461-2466.	1.6	67
363	Variation of Candidate Genes in Triglyceride Metabolism. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2000, 7, 309-315.	3.1	16
364	Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. <i>Diabetes Care</i> , 2000, 23, 1679-1685.	4.3	149
365	Hypertriglyceridemia Characterized by Low-Density Lipoprotein Phenotype and Lipoprotein Lipase Gene Mutation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 1263-70.	1.4	4
366	Apolipoprotein epsilon 2 Allele Is Associated With an Anti-atherogenic Lipoprotein Profile in Children: The Columbia University BioMarkers Study. <i>Pediatrics</i> , 2000, 106, 568-575.	1.0	30
367	Insulin resistance and cardiovascular disease. <i>Journal of Clinical Investigation</i> , 2000, 106, 453-458.	3.9	997

#	ARTICLE	IF	CITATIONS
368	Lipid Risk Factor Correlates of Ischemic Heart Disease as Diagnosed by Myocardial Perfusion Scintigraphy. <i>Preventive Cardiology</i> , 2000, 3, 33-39.	1.1	4
369	The role of small, dense low density lipoprotein (LDL): a new look. <i>International Journal of Cardiology</i> , 2000, 74, S17-S22.	0.8	120
370	Atherogenic lipoprotein phenotype in end-stage renal failure: Origin and extent of small dense low-density lipoprotein formation. <i>American Journal of Kidney Diseases</i> , 2000, 35, 852-862.	2.1	127
371	Triglycerides and atherosclerosis: to feast or fast. <i>Netherlands Journal of Medicine</i> , 2000, 56, 110-118.	0.6	17
372	Lipid-mediated endothelial dysfunction: a common factor to preeclampsia and chronic vascular disease. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2000, 92, 63-66.	0.5	58
373	Current perspectives on the management of hypertriglyceridemia. <i>American Heart Journal</i> , 2000, 140, 232-240.	1.2	40
374	Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension. <i>American Journal of Hypertension</i> , 2000, 13, 617-624.	1.0	7
375	Blood lipid response to 20 weeks of supervised exercise in a large biracial population: The HERITAGE family study. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 513-520.	1.5	138
376	Preventing, stopping, or reversing coronary artery disease—triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: The need for recognition and treatment. <i>Disease-a-Month</i> , 2000, 46, 421-503.	0.4	5
377	Subcutaneous and Visceral Adipose Tissue: Their Relation to the Metabolic Syndrome. <i>Endocrine Reviews</i> , 2000, 21, 697-738.	8.9	2,283
378	Novel Risk Factors for Atherosclerosis. <i>Mayo Clinic Proceedings</i> , 2000, 75, 369-380.	1.4	141
379	The small, dense LDL phenotype as a correlate of postprandial lipemia in men. <i>Atherosclerosis</i> , 2000, 153, 423-432.	0.4	42
380	Low density lipoprotein particle size and risk factors of insulin resistance syndrome. <i>Atherosclerosis</i> , 2000, 148, 141-149.	0.4	62
381	Lipoprotein correlates of LDL particle size. <i>Atherosclerosis</i> , 2000, 148, 151-158.	0.4	45
382	Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. <i>Atherosclerosis</i> , 2000, 148, 387-396.	0.4	96
383	Genetic factors associated with response of LDL subfractions to change in the nature of dietary fat. <i>Atherosclerosis</i> , 2000, 149, 387-394.	0.4	29
384	Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. <i>Atherosclerosis</i> , 2000, 152, 181-192.	0.4	65
385	Levels and correlates of LDL and VLDL particle sizes among children: the Bogalusa heart study. <i>Atherosclerosis</i> , 2000, 152, 441-449.	0.4	67

#	ARTICLE	IF	CITATIONS
386	Endothelial vasodilator function is related to low-density lipoprotein particle size and low-density lipoprotein vitamin E content in type 1 diabetes. <i>Journal of the American College of Cardiology</i> , 2000, 35, 292-299.	1.2	59
387	Distribution and cardiovascular risk correlates of serum triglycerides in young adults from a biracial community. <i>Atherosclerosis</i> , 2001, 155, 201-209.	0.4	16
388	Fibrinogen is an antioxidant that protects $\beta$ <sup>2</sup> -lipoproteins at physiological concentrations in a cell free system. <i>Atherosclerosis</i> , 2001, 158, 455-463.	0.4	37
389	Distribution and correlates of lipoproteins and their subclasses in black and white young adults. The Bogalusa Heart Study. <i>Atherosclerosis</i> , 2001, 159, 391-397.	0.4	16
390	DIETARY AND GENETIC EFFECTS ON LOW-DENSITY LIPOPROTEIN HETEROGENEITY. <i>Annual Review of Nutrition</i> , 2001, 21, 283-295.	4.3	96
391	Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. <i>American Journal of Medicine</i> , 2001, 110, 103-110.	0.6	157
392	Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. <i>Metabolism: Clinical and Experimental</i> , 2001, 50, 983-988.	1.5	40
393	Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control. <i>Diabetes Research and Clinical Practice</i> , 2001, 51, 107-114.	1.1	23
394	Risk factors for coronary heart disease in type 1 diabetic children: the influence of apoE phenotype and glycemic regulation. <i>Diabetes Research and Clinical Practice</i> , 2001, 54, 165-171.	1.1	5
395	Apolipoproteins B and A-I as predictors of risk of coronary artery disease. <i>Lancet, The</i> , 2001, 358, 2012-2013.	6.3	13
396	Dietary and Genetic Effects on LDL Heterogeneity. , 2001, 89, 12-22.		8
398	Prevention of a First Myocardial Infarction. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 359-367.	1.0	3
399	Development of a Rapid, Quantitative Method for LDL Subfractionation with Use of the Quantimetrix Lipoprint LDL System. <i>Clinical Chemistry</i> , 2001, 47, 266-274.	1.5	228
400	Effects of Peritoneal Dialysis with an Overnight Icodextrin Dwell on Parameters of Glucose and LIPID Metabolism. <i>Peritoneal Dialysis International</i> , 2001, 21, 275-281.	1.1	100
401	Lipoprotein subclasses and atherosclerosis. <i>Frontiers in Bioscience - Landmark</i> , 2001, 6, d355-365.	3.0	16
402	Lipid Disorders in Diabetic Nephropathy. , 0, , 175-192.		1
403	Lipoprotein subclasses and atherosclerosis. <i>Frontiers in Bioscience - Landmark</i> , 2001, 6, d355.	3.0	33
404	Hepatic Lipase as a Focal Point for the Development and Treatment of Coronary Artery Disease. <i>Journal of Investigative Medicine</i> , 2001, 49, 112-118.	0.7	22

#	ARTICLE	IF	CITATIONS
405	Postprandial lipid handling. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2001, 4, 93-98.	1.3	10
406	Visceral Fat Accumulation Contributes to Insulin Resistance, Small-Sized Low-Density Lipoprotein, and Progression of Coronary Artery Disease in Middle-Aged Non-Obese Japanese Men. <i>Japanese Circulation Journal</i> , 2001, 65, 193-199.	1.0	87
408	Perspectives on Vascular Biology and Diabetes. <i>Journal of Investigative Medicine</i> , 2001, 49, 100-103.	0.7	4
409	Current Lipid-lowering Strategies for the Treatment of Diabetic Dyslipidemia: An Integrated Approach to Therapy. , 2001, 11, 368-383.		4
410	Gender May Affect the Action of Garlic Oil on Plasma Cholesterol and Glucose Levels of Normal Subjects. <i>Journal of Nutrition</i> , 2001, 131, 1471-1478.	1.3	66
411	Atherogenic Lipoprotein Phenotype and Diet-Gene Interactions. <i>Journal of Nutrition</i> , 2001, 131, 340S-343S.	1.3	87
412	Effect of Alcohol on Postprandial Lipemia with and without Preprandial Exercise. <i>Journal of the American College of Nutrition</i> , 2001, 20, 58-64.	1.1	27
413	The effect of n <sup>~</sup> 3 fatty acids on low density lipoprotein subfractions. <i>Lipids</i> , 2001, 36, S91-S97.	0.7	34
414	Targeting triglycerides as prognostic indicators and determining lowest values for patient benefit. <i>Current Cardiology Reports</i> , 2001, 3, 424-432.	1.3	3
415	Diabetes and dyslipidemia. <i>Current Diabetes Reports</i> , 2001, 1, 93-95.	1.7	11
416	Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 11/2 years. <i>Kidney International</i> , 2001, 59, 2346-2356.	2.6	60
417	Low-density lipoprotein subclasses in children under 10 years of age. <i>Journal of Paediatrics and Child Health</i> , 2001, 37, 550-553.	0.4	15
418	Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis. <i>Diabetes/Metabolism Research and Reviews</i> , 2001, 17, 27-43.	1.7	60
419	Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. <i>American Journal of Cardiology</i> , 2001, 87, 1174-1180.	0.7	58
420	Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. <i>American Journal of Cardiology</i> , 2001, 88, 270-274.	0.7	120
422	Total Cholesterol/HDL Cholesterol Ratio vs LDL Cholesterol/HDL Cholesterol Ratio as Indices of Ischemic Heart Disease Risk in Men. <i>Archives of Internal Medicine</i> , 2001, 161, 2685.	4.3	413
423	Familial Combined Hyperlipidemia and Insulin Resistance. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 469-470.	1.1	15
424	The Role of Risk Factors in the Development of Atherosclerosis. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2001, 38, 401-440.	2.7	25

#	ARTICLE	IF	CITATIONS
426	Risk Factors for Coronary Disease: the Time for a Paradigm Shift?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2001, 39, 907-19.	1.4	10
427	Circulating Oxidized LDL Is a Useful Marker for Identifying Patients With Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 844-848.	1.1	469
428	Low Density Lipoprotein Particle Size and Risk of Early-Onset Myocardial Infarction in Women. <i>American Journal of Epidemiology</i> , 2001, 153, 939-945.	1.6	53
429	Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. <i>Lupus</i> , 2001, 10, 359-363.	0.8	40
430	Non-HDL High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality. <i>Archives of Internal Medicine</i> , 2001, 161, 1413.	4.3	547
431	Fluvastatin Lowers Atherogenic Dense Low-Density Lipoproteins in Postmenopausal Women With the Atherogenic Lipoprotein Phenotype. <i>Circulation</i> , 2001, 103, 1942-1948.	1.6	51
432	Effects of Monounsaturated Enriched Sunflower Oil on CHD Risk Factors Including LDL Size and Copper-Induced LDL Oxidation. <i>Journal of the American College of Nutrition</i> , 2001, 20, 320-326.	1.1	33
433	Physical exercise in dyslipoproteinemias: An update. <i>European Journal of Sport Science</i> , 2002, 2, 1-13.	1.4	3
436	Metabolic origins and clinical significance of LDL heterogeneity. <i>Journal of Lipid Research</i> , 2002, 43, 1363-1379.	2.0	713
437	Insulin Resistance, Impaired Postprandial Lipid Metabolism and Abdominal Obesity. <i>Medical Principles and Practice</i> , 2002, 11, 31-40.	1.1	42
438	Effect of Fluvastatin Slow-Release on Low Density Lipoprotein (LDL) Subfractions in Patients with Type 2 Diabetes Mellitus: Baseline LDL Profile Determines Specific Mode of Action. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 5485-5490.	1.8	57
439	Coagulation and Fibrinolysis in Diabetes. <i>Seminars in Vascular Medicine</i> , 2002, 2, 075-086.	2.1	21
440	Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2002, 110, 182-187.	0.6	29
441	The Complex Role of Triglycerides in Cardiovascular Disease. <i>Seminars in Vascular Medicine</i> , 2002, 02, 325-334.	2.1	54
442	Lovastatin and Extended-Release Niacin Combination Product: The First Drug Combination for the Management of Hyperlipidemia. <i>Heart Disease (Hagerstown, Md )</i> , 2002, 4, 124-137.	1.3	45
443	Hypertriglyceridemia: A Review Beyond Low-Density Lipoprotein. <i>Cardiology in Review</i> , 2002, 10, 163-172.	0.6	36
444	Different effects of diets rich in olive oil, rapeseed oil and sunflower-seed oil on postprandial lipid and lipoprotein concentrations and on lipoprotein oxidation susceptibility. <i>British Journal of Nutrition</i> , 2002, 87, 489-499.	1.2	40
445	Distribution and Cardiovascular Risk Correlates of Serum Triglycerides in Young Japanese Adults.. <i>Industrial Health</i> , 2002, 40, 28-35.	0.4	12

#	ARTICLE	IF	CITATIONS
446	A single daily dose of soybean phytosterols in ground beef decreases serum total cholesterol and LDL cholesterol in young, mildly hypercholesterolemic men,,,,. American Journal of Clinical Nutrition, 2002, 76, 57-64.	2.2	112
447	Treatment of Small Dense LDL. Journal of Atherosclerosis and Thrombosis, 2002, 9, 266-275.	0.9	28
448	A Ketogenic Diet Favorably Affects Serum Biomarkers for Cardiovascular Disease in Normal-Weight Men. Journal of Nutrition, 2002, 132, 1879-1885.	1.3	261
449	Adiposity, insulin and lipid metabolism in post-menopausal women. International Journal of Obesity, 2002, 26, 475-486.	1.6	28
450	Cardiovascular risks in obesity. Journal of Endocrinological Investigation, 2002, 25, 915-918.	1.8	8
451	The Significance of Measuring Non-HDL-Cholesterol. Preventive Cardiology, 2002, 5, 156-159.	1.1	23
452	Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis, 2002, 160, 41-48.	0.4	82
453	A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors. Atherosclerosis, 2002, 160, 185-193.	0.4	26
454	A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis, 2002, 162, 363-371.	0.4	59
455	Regulation of small dense LDL concentration in Korean and Scottish men and women. Atherosclerosis, 2002, 164, 187-193.	0.4	23
456	Very-low-carbohydrate weight-loss diets revisited.. Cleveland Clinic Journal of Medicine, 2002, 69, 849-849.	0.6	61
457	Physical Activity May Modulate Effects of ApoE Genotype on Lipid Profile. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 133-140.	1.1	82
458	Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochemical and Biophysical Research Communications, 2002, 295, 1156-1159.	1.0	153
459	CETP gene mutation (D442G) increases low-density lipoprotein particle size in patients with coronary heart disease. Clinica Chimica Acta, 2002, 322, 85-90.	0.5	17
460	Diabetic dyslipidemia. Atherosclerosis Supplements, 2002, 3, 47-51.	1.2	166
461	Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease. American Heart Journal, 2002, 144, 1026-1035.	1.2	67
462	N-3 fatty acids and diabetes. Biomedicine and Pharmacotherapy, 2002, 56, 397-406.	2.5	43
465	Cardiac Complications and Management. , 0, , 577-605.		0

#	ARTICLE	IF	CITATIONS
466	Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults. <i>Journal of Atherosclerosis and Thrombosis</i> , 2002, 9, 1-27.	0.9	166
467	Diagnosis of Familial Combined Hyperlipidemia Based on Lipid Phenotype Expression in 32 Families. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 274-282.	1.1	123
468	Small LDL and Its Clinical Importance as a New CAD Risk Factor: A Female Case Study. <i>Progress in Cardiovascular Nursing</i> , 2002, 17, 167-173.	0.5	22
469	Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I) trial. <i>American Journal of Cardiology</i> , 2002, 90, 89-94.	0.7	269
470	Atherogenic lipoproteins and diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2002, 16, 29-34.	1.2	25
471	Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2002, 18, 484-490.	1.7	44
472	Macrophages take up triacylglycerol-rich emulsions at a faster rate upon co-incubation with native and modified LDL: An investigation on the role of natural chylomicrons in atherosclerosis. <i>Journal of Cellular Biochemistry</i> , 2002, 84, 309-323.	1.2	18
473	Conway Memorial Lecture 2002 The dyslipidaemia of diabetes: lessons in the pathogenesis of atherosclerosis. <i>Irish Journal of Medical Science</i> , 2002, 171, 220-224.	0.8	0
474	Hyperglycaemia: the relation to dyslipidaemia and atherosclerosis. <i>Irish Journal of Medical Science</i> , 2002, 171, 161-164.	0.8	0
475	Hypertriglyceridemia and risk of coronary heart disease. <i>Current Cardiology Reports</i> , 2002, 4, 488-493.	1.3	47
476	Effects of prednisone withdrawal on the new metabolic triad in cyclosporine-treated kidney transplant patients. <i>Kidney International</i> , 2002, 62, 1839-1847.	2.6	40
477	Addition of glucose to a fatty meal delays chylomicrons and suppresses VLDL in healthy subjects. <i>European Journal of Clinical Investigation</i> , 2002, 32, 322-327.	1.7	27
478	Is the gender difference in LDL size explained by the metabolic complications of visceral obesity?. <i>European Journal of Clinical Investigation</i> , 2002, 32, 909-917.	1.7	23
479	Genetic influences contributing to LDL particle size in familial combined hyperlipidaemia. <i>European Journal of Human Genetics</i> , 2002, 10, 547-552.	1.4	12
480	Low-density lipoprotein particle size, central obesity, cardiovascular fitness, and insulin resistance syndrome markers in obese youths. <i>International Journal of Obesity</i> , 2002, 26, 1030-1035.	1.6	52
481	The Cardioprotective Effect of Wine on Human Blood Chemistry. <i>Annals of the New York Academy of Sciences</i> , 2002, 957, 337-340.	1.8	18
482	Analysis method for lipoproteins by high-performance liquid chromatography with sulfopropyl-ligand column and magnesium ion-containing eluents. <i>Analytical Biochemistry</i> , 2002, 308, 336-342.	1.1	5
483	The physiology of lipoproteins. <i>Journal of Nuclear Cardiology</i> , 2002, 9, 638-649.	1.4	84

#	ARTICLE	IF	CITATIONS
484	HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins. <i>Cardiovascular Drugs and Therapy</i> , 2003, 17, 53-62.	1.3	23
485	Postprandial lipemia and cardiovascular disease. <i>Current Atherosclerosis Reports</i> , 2003, 5, 437-444.	2.0	141
486	Lipid abnormalities in the metabolic syndrome. <i>Current Diabetes Reports</i> , 2003, 3, 65-72.	1.7	19
487	Increased susceptibility to low density lipoprotein oxidation in women with a history of pre-eclampsia. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2003, 110, 400-404.	1.1	18
488	Cardiovascular complications of diabetes: Prevention and management. <i>Clinical Cornerstone</i> , 2003, 5, 22-37.	1.0	6
489	Time-dependent lipid response on fluvastatin therapy of patients with hypercholesterolemia sensitive to apoE phenotype. <i>Vascular Pharmacology</i> , 2003, 40, 237-245.	1.0	6
490	A practical approach to risk assessment to prevent coronary artery disease and its complications. <i>American Journal of Cardiology</i> , 2003, 92, 19-26.	0.7	72
491	Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. <i>American Journal of Cardiology</i> , 2003, 92, 27-33.	0.7	103
492	Increased susceptibility to low density lipoprotein oxidation in women with a history of pre-eclampsia. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2003, 110, 400-404.	1.1	31
493	Low-density-lipoprotein peak particle size in a Mediterranean population. <i>European Journal of Clinical Investigation</i> , 2003, 33, 126-133.	1.7	40
494	Consistency of genetic inheritance mode and heritability patterns of triglyceride vs. high density lipoprotein cholesterol ratio in two Taiwanese family samples. <i>BMC Genetics</i> , 2003, 4, 7.	2.7	24
495	LDL phenotype B and other lipid abnormalities in patients with large vessel disease and small vessel disease. <i>Journal of the Neurological Sciences</i> , 2003, 214, 11-16.	0.3	20
496	European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, S1-S78.	3.1	52
497	Fenofibrate-Induced Hyperhomocysteinaemia. <i>Drug Safety</i> , 2003, 26, 81-91.	1.4	24
498	Metabolic Complications Associated with HIV Protease Inhibitor Therapy. <i>Drugs</i> , 2003, 63, 2555-2574.	4.9	85
499	Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. <i>American Journal of Medicine</i> , 2003, 115, 24-28.	0.6	118
500	Production of polyacrylamide gradient gel for lipoprotein electrophoretic separation. <i>Clinica Chimica Acta</i> , 2003, 338, 73-78.	0.5	2
501	Association between Diabetes Mellitus, Hypothyroidism or Hyperadrenocorticism, and Atherosclerosis in Dogs. <i>Journal of Veterinary Internal Medicine</i> , 2003, 17, 489-494.	0.6	116

#	ARTICLE	IF	CITATIONS
502	Measurement of plasma small-dense LDL concentration by a simplified ultracentrifugation procedure and immunoassay of apolipoprotein B. <i>Clinica Chimica Acta</i> , 2003, 334, 95-106.	0.5	22
503	High-sensitive C-reactive protein level and oxidative stress-related status in former athletes in relation to traditional cardiovascular risk factors. <i>Atherosclerosis</i> , 2003, 171, 321-326.	0.4	40
504	Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. <i>Atherosclerosis</i> , 2003, 171, 245-253.	0.4	94
505	Long-term effect of reduced carbohydrate or increased fiber intake on LDL particle size and HDL composition in subjects with type 2 diabetes. <i>Nutrition Research</i> , 2003, 23, 15-26.	1.3	7
506	Effects of stable fish oil and simvastatin on plasma lipoproteins in patients with hyperlipidemia. <i>Nutrition Research</i> , 2003, 23, 1027-1034.	1.3	6
507	Dyslipidaemia. <i>Lancet, The</i> , 2003, 362, 717-731.	6.3	314
508	A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , 2003, 25, 1074-1095.	1.1	120
509	Low density lipoprotein particles are small in patients with coronary vasospasm. <i>International Journal of Cardiology</i> , 2003, 87, 193-201.	0.8	26
510	Effect of atorvastatin on lipid parameters, LDL subtype distribution, hemorrheological parameters and adhesion molecule concentrations in patients with hypertriglyceridemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2003, 13, 87-92.	1.1	13
511	Statins and metabolic syndrome. <i>International Congress Series</i> , 2003, 1253, 243-246.	0.2	3
512	Charge-based heterogeneity of human plasma lipoproteins at hypertriglyceridemia: capillary isotachopheresis study. <i>International Journal of Biochemistry and Cell Biology</i> , 2003, 35, 530-543.	1.2	10
513	Dyslipidemia in Patients with Type 2 Diabetes. Relationships between Lipids, Kidney Disease and Cardiovascular Disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 1174-81.	1.4	46
514	Comparison of Low-Density Lipoprotein Size by Polyacrylamide Tube Gel Electrophoresis and Polyacrylamide Gradient Gel Electrophoresis. <i>American Journal of Clinical Pathology</i> , 2003, 119, 439-445.	0.4	22
515	Premenopausal Advantages in Postprandial Lipid Metabolism Are Lost in Women With Type 2 Diabetes. <i>Diabetes Care</i> , 2003, 26, 3243-3249.	4.3	30
516	Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension: A double-blind, placebo-controlled study. <i>Diabetes Care</i> , 2003, 26, 2588-2594.	4.3	116
517	Low-Density Lipoprotein Subfractions and Cardiovascular Risk in Hypertension. <i>Hypertension</i> , 2003, 41, 528-533.	1.3	31
518	A novel and simple method for quantification of small, dense LDL. <i>Journal of Lipid Research</i> , 2003, 44, 2193-2201.	2.0	171
519	Genome-wide scan for quantitative trait loci influencing LDL size and plasma triglyceride in familial hypertriglyceridemia. <i>Journal of Lipid Research</i> , 2003, 44, 2161-2168.	2.0	26

#	ARTICLE	IF	CITATIONS
520	Effects of Insulin Resistance and Type 2 Diabetes on Lipoprotein Subclass Particle Size and Concentration Determined by Nuclear Magnetic Resonance. <i>Diabetes</i> , 2003, 52, 453-462.	0.3	539
521	Medical Management of Hyperlipidemia/Dyslipidemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2445-2461.	1.8	48
522	Obesity, Glucose Intolerance and Diabetes and Their Links to Cardiovascular Disease. Implications for Laboratory Medicine. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 1266-78.	1.4	34
523	Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2003, 96, 825-832.	0.2	62
524	Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4525-4532.	1.8	199
525	Effect of Atorvastatin on the Concentration, Relative Distribution, and Chemical Composition of Lipoprotein Subfractions in Patients With Dyslipidemias of Type IIA and IIB. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 42, 304-310.	0.8	16
526	Effect of Desirable Fasting Triglycerides on the Postprandial Response to Dietary Fat. <i>Journal of Investigative Medicine</i> , 2003, 51, 50-55.	0.7	17
527	Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. <i>Biochemical Society Transactions</i> , 2003, 31, 1066-1069.	1.6	184
528	The extended postprandial phase in diabetes. <i>Biochemical Society Transactions</i> , 2003, 31, 1085-1089.	1.6	9
529	Exaggerated postprandial lipaemia and lower post-heparin lipoprotein lipase activity in middle-aged men. <i>Clinical Science</i> , 2003, 105, 457-466.	1.8	33
530	The scientific basis of recent US guidance on sugars intake. <i>American Journal of Clinical Nutrition</i> , 2003, 78, 827S-833S.	2.2	82
531	Life Style and Cardiovascular Risk Factors in the Japanese Population-From an Epidemiological Survey on Serum Lipid Levels in Japan 1990. Part 2: Association of Lipid Parameters with Hypertension. <i>Journal of Atherosclerosis and Thrombosis</i> , 2003, 10, 176-185.	0.9	13
532	Fluvastatin Increases LDL Particle Size and Reduces Oxidative Stress in Patients with Hyperlipidemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2003, 10, 343-347.	0.9	10
533	Pleiotropy and Heterogeneity in the Expression of Atherogenic Lipoproteins: The IRAS Family Study. <i>Human Heredity</i> , 2003, 55, 46-50.	0.4	22
534	Metabolic Syndrome and Cardiovascular Disease. <i>Sunhwan'gi</i> , 2003, 33, 645.	0.3	15
535	Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2003, 284, E1112-E1118.	1.8	61
536	Relationship between High-density Lipoprotein-cholesterol and Malondialdehyde-modified Low-density Lipoprotein Concentrations. <i>Journal of Atherosclerosis and Thrombosis</i> , 2003, 10, 72-78.	0.9	24
538	Metabolic Syndrome: Maladaptation to a Modern World. <i>Journal of the Royal Society of Medicine</i> , 2004, 97, 511-520.	1.1	20

#	ARTICLE	IF	CITATIONS
539	Gene by Smoking Interaction: Evidence for Effects on Low-Density Lipoprotein Size and Plasma Triglyceride and High-Density Lipoprotein Cholesterol Levels. <i>Human Biology</i> , 2004, 76, 863-876.	0.4	12
540	Inhibition of HMG-CoA Reductase with Cerivastatin Lowers Dense Low Density Lipoproteins in Patients with Elevated Fasting Glucose, Impaired Glucose Tolerance and Type 2 Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2004, 112, 269-277.	0.6	11
541	Qualitative Effect of Fenofibrate and Quantitative Effect of Atorvastatin on LDL Profile in Combined Hyperlipidemia with dense LDL. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2004, 112, 241-247.	0.6	24
542	Gene:Environment Interactions and Coronary Heart Disease Risk. , 2004, 93, 29-40.		12
543	Relationship between low-density lipoprotein subclasses and asymptomatic atherosclerosis in subjects from the atherosclerosis risk in communities (ARIC) Study. <i>Biomarkers</i> , 2004, 9, 190-202.	0.9	16
544	Association of the APOLIPOPROTEIN A1/C3/A4/A5 Gene Cluster With Triglyceride Levels and LDL Particle Size in Familial Combined Hyperlipidemia. <i>Circulation Research</i> , 2004, 94, 993-999.	2.0	92
545	Genetics of familial combined hyperlipidemia and risk of coronary heart disease. <i>Human Molecular Genetics</i> , 2004, 13, 149R-160.	1.4	79
546	New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders. <i>Archives of Internal Medicine</i> , 2004, 164, 697.	4.3	166
547	Divergent Effects of the Catalytic and Bridging Functions of Hepatic Lipase on Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1696-1702.	1.1	23
548	Genetics of LDL particle heterogeneity. <i>Journal of Lipid Research</i> , 2004, 45, 1008-1026.	2.0	37
549	Clinical Significance of Small Dense Low-Density Lipoprotein Cholesterol Levels Determined by the Simple Precipitation Method. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 558-563.	1.1	113
550	Elevated Remnant-Like Particle Cholesterol Concentration. <i>Circulation</i> , 2004, 109, 1918-1925.	1.6	158
551	Atherogenic Lipoprotein Particles in Atherosclerosis. <i>Circulation</i> , 2004, 109, III-2-III-7.	1.6	319
552	Distribution of low-density lipoprotein particle size in healthy Korean adult males. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 235-7.	1.4	5
553	Treating dyslipidaemia in the patient with type 2 diabetes. <i>European Heart Journal Supplements</i> , 2004, 6, C28-C33.	0.0	6
554	Low-Density Lipoprotein Particle Size Loci in Familial Combined Hyperlipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1942-1950.	1.1	37
555	Low-Density Lipoprotein Particle Size and Its Regulatory Factors in School Children. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2923-2927.	1.8	26
556	Metabolic syndrome: maladaptation to a modern world. <i>Journal of the Royal Society of Medicine</i> , 2004, 97, 511-520.	1.1	24

#	ARTICLE	IF	CITATIONS
557	Lipids and Lipoproteins in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 1496-1504.	4.3	585
558	In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy. <i>Journal of Lipid Research</i> , 2004, 45, 1459-1467.	2.0	25
559	Subclasses of Low-Density Lipoprotein and Very Low-Density Lipoprotein in Familial Combined Hyperlipidemia: Relationship to Multiple Lipoprotein Phenotype. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 744-749.	1.1	42
560	Low Density Lipoprotein-Heterogeneity als prognostischer Marker kardiovaskulärer Erkrankungen / Low density lipoprotein heterogeneity for risk evaluation of cardiovascular disease. <i>Laboratoriums Medizin</i> , 2004, 28, 447-452.	0.1	0
561	The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2004, 6, 133-156.	2.2	122
562	LDL heterogeneity revisited: lesson for the metabolic syndrome from a new interpopulation study?. <i>European Journal of Clinical Investigation</i> , 2004, 34, 719-722.	1.7	10
563	Cardiovascular and Hormonal Aspects of Very-Low-Carbohydrate Ketogenic Diets. <i>Obesity</i> , 2004, 12, 115S-23S.	4.0	42
564	The metabolic syndrome: Diagnosis and treatment. <i>Clinical Cornerstone</i> , 2004, 6, S5-S13.	1.0	14
565	Treatment of type IIb familial combined hyperlipidemia with the combination pravastatin-piperazine sultosilate. <i>European Journal of Pharmacology</i> , 2004, 496, 205-212.	1.7	5
566	Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. <i>American Journal of Cardiology</i> , 2004, 94, 219-222.	0.7	132
567	Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia. <i>Archives of Medical Research</i> , 2004, 35, 235-240.	1.5	34
568	Low-density lipoprotein particle number and risk for cardiovascular disease. <i>Current Atherosclerosis Reports</i> , 2004, 6, 381-387.	2.0	175
569	Diet and low-density lipoprotein particle size. <i>Current Atherosclerosis Reports</i> , 2004, 6, 453-460.	2.0	17
570	High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 160-165.	6.7	73
571	Metabolic abnormalities: triglyceride and low-density lipoprotein. <i>Endocrinology and Metabolism Clinics of North America</i> , 2004, 33, 405-415.	1.2	87
572	Tratamiento de la dislipemia diabética con fármacos hipolipemiantes. Nuevos conceptos. <i>Clínica E Investigaci³n En Arteriosclerosis</i> , 2004, 16, 160-169.	0.4	4
573	Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of Type 2 Diabetes and Familial Combined Hyperlipidemia in Coronary Artery Disease Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2601-2607.	1.8	398
574	Oolong tea increases plasma adiponectin levels and low-density lipoprotein particle size in patients with coronary artery disease. <i>Diabetes Research and Clinical Practice</i> , 2004, 65, 227-234.	1.1	77

#	ARTICLE	IF	CITATIONS
575	Association between LDL particle size and postprandial increase of remnant-like particles in Japanese type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2004, 66, 245-252.	1.1	9
576	Association of apolipoprotein A5 variants with LDL particle size and triglyceride in Japanese Americans. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2004, 1688, 1-9.	1.8	54
577	Measurement of the serum lipoprotein lipase concentration is useful for studying triglyceride metabolism: comparison with postheparin plasma. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 526-531.	1.5	32
578	Fluvastatin improves endothelial dysfunction in overweight postmenopausal women through small dense low-density lipoprotein reduction. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 733-739.	1.5	18
579	Atorvastatin Reduces Remnant Lipoproteins and Small, Dense Low-Density Lipoproteins Regardless of the Baseline Lipid Pattern. <i>Preventive Cardiology</i> , 2004, 7, 154-160.	1.1	20
580	A new approach to the quantitative measurement of dense LDL subfractions. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2004, 14, 73-80.	1.1	9
581	Elevated soluble tumor necrosis factor receptor levels in non-obese adults with the atherogenic dyslipoproteinemia. <i>Atherosclerosis</i> , 2004, 177, 77-81.	0.4	14
583	Mitochondrial injury in steatohepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1095-1105.	0.8	132
584	Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies. <i>Clinical Science</i> , 2004, 107, 221-232.	1.8	42
585	Importance and Management of Dyslipidemia in the Metabolic Syndrome. <i>American Journal of the Medical Sciences</i> , 2005, 330, 295-302.	0.4	29
586	High Prevalence of C-Reactive Protein Elevation with Normal Triglycerides (100-149mg/dL): Are Triglyceride Levels Below 100mg/dL More Optimal in Coronary Heart Disease Risk Assessment?. <i>American Journal of the Medical Sciences</i> , 2005, 329, 173-177.	0.4	7
587	Modification of Lipoproteins by Very Low-Carbohydrate Diets. <i>Journal of Nutrition</i> , 2005, 135, 1339-1342.	1.3	130
588	Postprandial changes in LDL phenotypes in patients with myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2005, 35, 171-179.	1.7	19
589	Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study). <i>American Journal of Cardiology</i> , 2005, 95, 869-871.	0.7	63
590	Predictors of Low-Density Lipoprotein Particle Size in a High-Risk African-American Population. <i>American Journal of Cardiology</i> , 2005, 95, 1320-1323.	0.7	12
591	The metabolic basis of atherogenic dyslipidemia. <i>Clinical Cornerstone</i> , 2005, 7, 27-35.	1.0	41
592	Lack of effect of dietary n-6:n-3 PUFA ratio on plasma lipids and markers of insulin responses in Indian Asians living in the UK. <i>European Journal of Nutrition</i> , 2005, 44, 26-32.	1.8	31
593	Influence of dietary carbohydrate and fat on LDL and HDL particle distributions. <i>Current Atherosclerosis Reports</i> , 2005, 7, 455-459.	2.0	70

#	ARTICLE	IF	CITATIONS
594	Measurement of Small Dense Low-density Lipoprotein Particles. <i>Journal of Atherosclerosis and Thrombosis</i> , 2005, 12, 67-72.	0.9	119
595	Evidence for an Exaggerated Postprandial Lipemia in Chronic Paraplegia. <i>Journal of Spinal Cord Medicine</i> , 2005, 28, 320-325.	0.7	40
596	Hyperlipidemic Subjects Have Reduced Uptake of Newly Absorbed Vitamin E into Their Plasma Lipoproteins, Erythrocytes, Platelets, and Lymphocytes, as Studied by Deuterium-Labeled $\alpha$ -Tocopherol Biokinetics. <i>Journal of Nutrition</i> , 2005, 135, 58-63.	1.3	22
597	Lipid Triad or Atherogenic Lipoprotein Phenotype: A Role in Cardiovascular Prevention?. <i>Journal of Atherosclerosis and Thrombosis</i> , 2005, 12, 237-239.	0.9	70
600	Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Small, Dense LDL Particles in Human Plasma. <i>Clinical Chemistry</i> , 2005, 51, 2264-2273.	1.5	158
601	The Predictive Value of Lipid Markers in Vascular Disease. <i>Current Pharmaceutical Design</i> , 2005, 11, 2209-2224.	0.9	8
602	Dietary and Genetic Probes of Atherogenic Dyslipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2265-2272.	1.1	111
603	Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?. <i>Journal of Lipid Research</i> , 2005, 46, 389-403.	2.0	202
604	Apolipoprotein A5 and Hypertriglyceridemia. <i>Clinical Chemistry</i> , 2005, 51, 295-297.	1.5	24
605	Significance of small dense low-density lipoproteins as coronary risk factor in diabetic and non-diabetic Korean populations. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 431-7.	1.4	7
606	Common Genetic and Environmental Effects on Lipid Phenotypes: The HERITAGE Family Study. <i>Human Heredity</i> , 2005, 59, 34-40.	0.4	12
607	New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. <i>Diabetes and Metabolism</i> , 2005, 31, 429-439.	1.4	99
608	Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size. <i>Atherosclerosis</i> , 2005, 180, 127-135.	0.4	27
609	Low density lipoprotein non-esterified fatty acids and lipoprotein lipase in diabetes. <i>Atherosclerosis</i> , 2005, 181, 109-114.	0.4	26
610	A genome wide quantitative trait linkage analysis for serum lipids in type 2 diabetes in an African population. <i>Atherosclerosis</i> , 2005, 181, 389-397.	0.4	35
611	Evidence of QTLs on chromosomes 13q and 14q for triglycerides before and after 20 weeks of exercise training: The HERITAGE Family Study. <i>Atherosclerosis</i> , 2005, 182, 349-360.	0.4	18
612	Compensatory Hyperinsulinemia and the Development of an Atherogenic Lipoprotein Profile: The Price Paid to Maintain Glucose Homeostasis in Insulin-Resistant Individuals. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005, 34, 49-62.	1.2	99
613	High-Density Lipoprotein Subclass Distribution in Individuals of Asian Indian Descent: The National Asian Indian Heart Disease Project. <i>Preventive Cardiology</i> , 2005, 8, 81-86.	1.1	30

#	ARTICLE	IF	CITATIONS
614	NASH: a mitochondrial disease. <i>Journal of Hepatology</i> , 2005, 42, 928-940.	1.8	372
615	Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 227-234.	1.5	79
616	Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin. <i>International Journal of Cardiology</i> , 2005, 104, 338-345.	0.8	24
617	Atherogenic lipoprotein subfraction profile in preeclamptic women with and without high triglycerides: different pathophysiologic subsets in preeclampsia. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 1504-1509.	1.5	37
618	A New Perspective in the Treatment of Dyslipidemia. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2005, 4, 311-317.	1.8	8
619	Drug Treatment in the Metabolic Syndrome. , 2005, , 431-461.		1
620	Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy. <i>Clinics in Laboratory Medicine</i> , 2006, 26, 847-870.	0.7	619
621	Diabetic Dyslipidemia and the Heart. <i>Heart Failure Clinics</i> , 2006, 2, 37-52.	1.0	1
622	Low-density lipoprotein size and cardiovascular risk assessment. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 1-14.	0.2	213
623	Autoantibodies to oxidized LDL and cardiovascular risk: The Framingham Offspring Study. <i>Atherosclerosis</i> , 2006, 189, 364-368.	0.4	36
624	Polyacrylamide Gradient Gel Electrophoresis of Lipoprotein Subclasses. <i>Clinics in Laboratory Medicine</i> , 2006, 26, 803-846.	0.7	39
625	Familial Hypercholesterolemia Associated with Coronary Atherosclerosis in Swine Bearing Different Alleles for Apolipoprotein B. <i>Annals of the New York Academy of Sciences</i> , 1994, 748, 283-292.	1.8	27
626	Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 599-604.	1.5	29
627	Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 879-884.	1.5	29
628	Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 885-891.	1.5	71
629	Enhancement of serum lipoprotein lipase mass levels by intensive insulin therapy. <i>Diabetes Research and Clinical Practice</i> , 2006, 72, 61-67.	1.1	8
630	The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension. <i>Diabetes Research and Clinical Practice</i> , 2006, 74, 242-248.	1.1	16
631	Low-density lipoprotein size and cardiovascular prevention. <i>European Journal of Internal Medicine</i> , 2006, 17, 77-80.	1.0	19

#	ARTICLE	IF	CITATIONS
632	Should we measure routinely the LDL peak particle size?. International Journal of Cardiology, 2006, 107, 166-170.	0.8	75
633	Significance of Small Dense Low-Density Lipoprotein as a Risk Factor for Coronary Artery Disease and Acute Coronary Syndrome. Yonsei Medical Journal, 2006, 47, 405.	0.9	38
634	Carbohydrate Restriction Alters Lipoprotein Metabolism by Modifying VLDL, LDL, and HDL Subfraction Distribution and Size in Overweight Men. Journal of Nutrition, 2006, 136, 384-389.	1.3	81
635	Predominance of Small Dense Low-Density Lipoproteins and Abnormal Glucose Regulation in Patients With Acute Coronary Syndrome. Circulation Journal, 2006, 70, 393-401.	0.7	12
636	Physical activity, fitness and cardiovascular disease risk in adults: interactions with insulin resistance and obesity. Clinical Science, 2006, 110, 409-425.	1.8	132
637	Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia. American Journal of Clinical Nutrition, 2006, 83, 1025-1031.	2.2	277
638	The Role of Small, Dense Low-Density-Lipoproteins in Non-Coronary Forms of Atherosclerosis. Vascular Disease Prevention, 2006, 3, 269-274.	0.2	2
639	HOMOCYSTEINE AND MALONDIALDEHYDE AS PREDICTORS OF RESTENOSIS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION. ASAIO Journal, 2006, 52, 22A.	0.9	1
640	Omega-3 Fatty Acids. Journal of Cardiovascular Nursing, 2006, 21, 17-24.	0.6	42
641	Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Current Opinion in Lipidology, 2006, 17, 412-417.	1.2	103
642	I405V polymorphism of the cholesteryl ester transfer protein (CETP) gene in young and very old people. Archives of Gerontology and Geriatrics, 2006, 43, 213-221.	1.4	24
643	Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clinical Cardiology, 2006, 29, 268-273.	0.7	47
644	The Clinical Relevance of Low-Density-Lipoproteins Size Modulation by Statins. Cardiovascular Drugs and Therapy, 2006, 20, 205-217.	1.3	63
645	Molecular Basis of Obesity and the Risk for Cardiovascular Disease. Herz, 2006, 31, 200-206.	0.4	13
646	Dietary carbohydrate and cholesterol influence the number of particles and distributions of lipoprotein subfractions in guinea pigs. Journal of Nutritional Biochemistry, 2006, 17, 773-779.	1.9	14
647	Component Analysis of HPLC Profiles of Unique Lipoprotein Subclass Cholesterols for Detection of Coronary Artery Disease. Clinical Chemistry, 2006, 52, 2049-2053.	1.5	41
648	Plasma Phospholipid Transfer Protein Activity Is Decreased in Type 2 Diabetes During Treatment With Atorvastatin: A Role for Apolipoprotein E?. Diabetes, 2006, 55, 1491-1496.	0.3	24
649	Increased Small Low-Density Lipoprotein Particle Number. Circulation, 2006, 113, 20-29.	1.6	290

#	ARTICLE	IF	CITATIONS
650	Disparate LDL Phenotypic Classification among 4 Different Methods Assessing LDL Particle Characteristics. <i>Clinical Chemistry</i> , 2006, 52, 1722-1727.	1.5	92
651	REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 383-392.	1.8	132
652	Tree nuts and the lipid profile: a review of clinical studies. <i>British Journal of Nutrition</i> , 2006, 96, S68-S78.	1.2	160
653	Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. <i>Diabetes and Vascular Disease Research</i> , 2006, 3, 39-44.	0.9	53
654	Atherogenic Lipoprotein Phenotype and Low-Density Lipoproteins Size and Subclasses in Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 186-189.	1.8	105
655	Update on the role of the atherogenic lipoprotein phenotype in cardiovascular prevention. <i>Future Cardiology</i> , 2007, 3, 553-558.	0.5	1
656	Mechanisms of Disease: lessons from ethnicity in the role of triglyceride metabolism in ischemic heart disease. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 530-538.	2.9	19
657	Triglycerides and Risk for Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 336.	3.8	102
658	Comparison of Apolipoprotein B and Non-HDL High-Density Lipoprotein Cholesterol for Identifying Coronary Artery Disease Risk Based on Receiver Operating Curve Analysis. <i>American Journal of Clinical Pathology</i> , 2007, 127, 449-455.	0.4	16
659	Physiological Basis of Aging and Geriatrics. , 0, , .		28
660	Calculated low-density lipoprotein cholesterol remains a viable and important test for screening and targeting therapy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 1319-25.	1.4	10
661	Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 53-72.	1.4	92
662	Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy. <i>European Journal of Endocrinology</i> , 2007, 156, 361-367.	1.9	27
663	Metabolic Consequences of Obesity and Body Fat Pattern: Lessons from Migrant Studies. <i>Novartis Foundation Symposium</i> , 1996, 201, 54-67.	1.2	19
664	Alternate approaches to managing lipid-associated cardiovascular risk. <i>Future Lipidology</i> , 2007, 2, 157-163.	0.5	0
665	Metabolic Effects of Protease Inhibitor-Sparing Antiretroviral Regimens Given as Initial Treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 540-550.	0.9	47
666	Dyslipidemia, Metabolic Syndrome and Vascular Disease Among Asian Indians. <i>Vascular Disease Prevention</i> , 2007, 4, 250-259.	0.2	1
667	The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 642-652.	1.0	37

#	ARTICLE	IF	CITATIONS
668	Racial differences in coronary artery calcification are not attributed to differences in lipoprotein particle sizes: The Heart Strategies Concentrating on Risk Evaluation (Heart SCORE) Study. <i>American Heart Journal</i> , 2007, 153, 328-334.	1.2	40
669	Circadian rhythm of serum concentration of small dense low-density lipoprotein cholesterol. <i>Clinica Chimica Acta</i> , 2007, 376, 96-100.	0.5	12
670	Hypertriglyceridemia and cardiovascular risk reduction. <i>Clinical Therapeutics</i> , 2007, 29, 763-777.	1.1	113
671	Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients. <i>Diabetes Research and Clinical Practice</i> , 2007, 78, 34-41.	1.1	34
672	Atherosclerosis Pathophysiology and the Role of Novel Risk Factors: A Clinicobiochemical Perspective. <i>Angiology</i> , 2007, 58, 513-522.	0.8	173
673	Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1246-1261.	3.0	280
674	Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. <i>Current Medical Research and Opinion</i> , 2007, 23, 1169-1176.	0.9	102
677	Factors Predictive of Cardiovascular Disease in Patients With Type-2 Diabetes and Hypercholesterolemia. ESODIAH Study. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2007, 60, 251-258.	0.4	4
678	Non-HDL cholesterol versus Apolipoprotein B in the identification of dyslipidemic phenotypes associated with cardiovascular risk in type 2 diabetic dyslipoproteinemia. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2007, 1, 29-36.	1.8	5
679	Ethnic differences in low-density lipoprotein particle size in hypertensive adults. <i>Journal of Clinical Lipidology</i> , 2007, 1, 218-224.	0.6	11
680	A retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy methylglutaryl coenzyme A reductase therapy in HIV-infected patients with hyperlipidemia. <i>Journal of Clinical Lipidology</i> , 2007, 1, 634-639.	0.6	11
682	Incidence and Risk Factors of Insulin Resistance Syndrome in 20-59 Year-Old Korean Male Workers. <i>Journal of Korean Medical Science</i> , 2007, 22, 968.	1.1	7
683	A Combination of Psyllium and Plant Sterols Alters Lipoprotein Metabolism in Hypercholesterolemic Subjects by Modifying the Intravascular Processing of Lipoproteins and Increasing LDL Uptake. <i>Journal of Nutrition</i> , 2007, 137, 1165-1170.	1.3	31
685	Small, dense low-density-lipoproteins and the metabolic syndrome. <i>Diabetes/Metabolism Research and Reviews</i> , 2007, 23, 14-20.	1.7	64
687	Associations between USF1 gene variants and cardiovascular risk factors in the Quebec Family Study. <i>Clinical Genetics</i> , 2007, 71, 245-253.	1.0	15
688	Low-density lipoprotein subfraction profiles in dialysis patients. <i>Nephrology</i> , 1997, 3, 169-177.	0.7	7
689	Who needs to care about small, dense low-density lipoproteins?. <i>International Journal of Clinical Practice</i> , 2007, 61, 1949-1956.	0.8	62
690	Do age and baseline LDL cholesterol levels determine the effect of regular exercise on plasma lipoprotein cholesterol and apolipoprotein B levels?. <i>European Journal of Applied Physiology</i> , 2007, 101, 621-628.	1.2	8

#	ARTICLE	IF	CITATIONS
691	Plasma Lipoproteins and Triacylglycerol are Predictors of Small, Dense LDL Particles. <i>Lipids</i> , 2007, 42, 403-409.	0.7	39
692	HDL Composition Regulates Displacement of Cell Surface-Bound Hepatic Lipase. <i>Lipids</i> , 2008, 43, 793-804.	0.7	14
693	Is it LDL particle size or number that correlates with risk for cardiovascular disease?. <i>Current Atherosclerosis Reports</i> , 2008, 10, 377-385.	2.0	78
694	Triglycerides and risk for coronary artery disease. <i>Current Atherosclerosis Reports</i> , 2008, 10, 386-390.	2.0	92
695	Fatty liver, insulin resistance, and dyslipidemia. <i>Current Diabetes Reports</i> , 2008, 8, 60-64.	1.7	115
696	Microchip-based small, dense low-density lipoproteins assay for coronary heart disease risk assessment. <i>Electrophoresis</i> , 2008, 29, 1932-1941.	1.3	21
697	Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients. <i>Journal of Infection</i> , 2008, 57, 47-54.	1.7	17
698	The atherogenic lipoprotein phenotype is not caused by a mutation in the coding region of the low density lipoprotein receptor gene. <i>Clinical Genetics</i> , 1997, 51, 236-240.	1.0	15
699	Dyslipidemia in children with type 2 diabetes vs. obesity. <i>Pediatric Diabetes</i> , 2008, 9, 115-121.	1.2	24
700	Lipid-Lowering Efficacy and Safety After Switching to Atazanavir-Ritonavir-Based Highly Active Antiretroviral Therapy in Patients with Human Immunodeficiency Virus. <i>Pharmacotherapy</i> , 2008, 28, 323-330.	1.2	29
701	Intrafamilial variability in the clinical expression of familial hypercholesterolemia: importance of risk factor determination for genetic counselling. <i>Clinical Genetics</i> , 2008, 43, 295-299.	1.0	27
702	Genetic and environmental influences on LDL subclass phenotypes. <i>Clinical Genetics</i> , 1994, 46, 64-70.	1.0	31
703	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. <i>American Journal of Cardiology</i> , 2008, 102, 1K-34K.	0.7	371
704	No Evidence of Increased Risk for Certain Highly Atherogenic Lipoprotein Phenotypes in HIV-infected Patients. <i>Archives of Medical Research</i> , 2008, 39, 84-91.	1.5	2
705	The Metabolic Syndrome. <i>Endocrine Reviews</i> , 2008, 29, 777-822.	8.9	1,513
706	Impact of Obesity on Cardiovascular Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 663-684.	1.2	108
707	El laboratorio cl�nico y las dislipemias. <i>Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2008, 55, 89-96.	0.8	4
708	Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial. <i>Journal of the American College of Cardiology</i> , 2008, 51, 724-730.	1.2	534

#	ARTICLE	IF	CITATIONS
709	Lipid Levels in the Post-Acute Coronary Syndrome Setting. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1446-1447.	1.2	16
710	The importance of non-HDL cholesterol reporting in lipid management. <i>Journal of Clinical Lipidology</i> , 2008, 2, 267-273.	0.6	145
713	A rapid 3% polyacrylamide slab gel electrophoresis method for high through put screening of LDL phenotype. <i>Lipids in Health and Disease</i> , 2008, 7, 47.	1.2	13
714	Genetic studies on the APOA1-C3-A5 gene cluster in Asian Indians with premature coronary artery disease. <i>Lipids in Health and Disease</i> , 2008, 7, 33.	1.2	35
715	Making the Connection Between Diet and Nutrition and Cardiovascular and Alzheimer's Diseases. <i>Explore: the Journal of Science and Healing</i> , 2008, 4, 148-153.	0.4	1
716	Serum concentration of small dense low-density lipoprotein-cholesterol during oral glucose tolerance test and oral fat tolerance test. <i>Clinica Chimica Acta</i> , 2008, 387, 36-41.	0.5	11
717	Genetic association study of APOA1/C3/A4/A5 gene cluster and haplotypes on triglyceride and HDL cholesterol in a community-based population. <i>Clinica Chimica Acta</i> , 2008, 388, 78-83.	0.5	33
718	Small dense LDL particles and metabolic syndrome in a sample of middle-aged women. Findings from Progetto Atena. <i>Clinica Chimica Acta</i> , 2008, 388, 179-183.	0.5	29
719	EFFECT OF EZETIMIBE ON LIPOPROTEIN SUBFRACTION CONCENTRATIONS: THE ROLE OF ATORVASTATIN PRETREATMENT. <i>Atherosclerosis Supplements</i> , 2008, 9, 188.	1.2	3
720	Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. <i>Atherosclerosis</i> , 2008, 197, 237-241.	0.4	66
721	Chapter 8 Atherogenic Lipoprotein Subprofiling. <i>Advances in Clinical Chemistry</i> , 2008, , 295-317.	1.8	10
722	Insulin Resistance and Atherosclerosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 603-621.	1.2	82
723	Ezetimibe: cholesterol lowering and beyond. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 447-470.	0.6	125
724	The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2295-2303.	0.9	18
725	LDL Species Heterogeneity in the Atherogenic Dyslipidemia of Polycystic Ovary Syndrome. <i>American Journal of Clinical Pathology</i> , 2008, 129, 802-810.	0.4	13
726	LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?. <i>Clinical Diabetes</i> , 2008, 26, 8-13.	1.2	15
727	Antiretroviral Therapy is Associated With an Atherogenic Lipoprotein Phenotype Among HIV-1-Infected Men in the Multicenter AIDS Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 281-288.	0.9	73
728	Overproduction of Very Low-Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1225-1236.	1.1	639

#	ARTICLE	IF	CITATIONS
729	Role of lipoprotein lipase in triglyceride metabolism: potential therapeutic target. <i>Future Lipidology</i> , 2008, 3, 385-397.	0.5	22
730	Clinical Relevance of Non-HDL Cholesterol in Patients With Diabetes. <i>Clinical Diabetes</i> , 2008, 26, 3-7.	1.2	52
731	Smoking and small, dense low-density lipoprotein particles: Cross-sectional study. <i>Nicotine and Tobacco Research</i> , 2008, 10, 1391-1395.	1.4	10
732	Lipoprotein separation in a novel iodixanol density gradient, for composition, density, and phenotype analysis. <i>Journal of Lipid Research</i> , 2008, 49, 1364-1371.	2.0	31
733	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 319-335.	0.9	227
734	Hypothyroidism Results in Small Dense LDL Independent of IRS Traits and Hypertriglyceridemia. <i>Endocrine Journal</i> , 2008, 55, 381-389.	0.7	33
735	Nutrition and Cardiovascular Disease. <i>Lippincott S Bone and Joint Newsletter</i> , 2008, 34, 1-4.	0.0	0
736	Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. <i>Current Opinion in Lipidology</i> , 2008, 19, 355-361.	1.2	98
737	<i>Nutritional Genomics and</i> Dietetic Professional Practice. <i>Canadian Journal of Dietetic Practice and Research</i> , 2008, 69, 177-182.	0.5	7
738	Protein in optimal health: heart disease and type 2 diabetes. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 1571S-1575S.	2.2	113
739	Advances in Lipid Testing and Management in Patients with Diabetes Mellitus. <i>Endocrine Practice</i> , 2009, 15, 641-652.	1.1	3
740	In Vivo Insulin Sensitivity and Lipoprotein Particle Size and Concentration in Black and White Children. <i>Diabetes Care</i> , 2009, 32, 2087-2093.	4.3	55
741	Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size. <i>Journal of Lipid Research</i> , 2009, 50, 2398-2411.	2.0	21
742	Aortic stiffness in diabetes mellitus â€“ association with glutamine and heat shock protein 70 expression: a pilot study based on an experimental rodent model. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 267-274.	1.5	12
743	Ion Mobility Analysis of Lipoprotein Subfractions Identifies Three Independent Axes of Cardiovascular Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1975-1980.	1.1	147
744	Comparison of the effects of four commercially available weight-loss programmes on lipid-based cardiovascular risk factors. <i>Public Health Nutrition</i> , 2009, 12, 799-807.	1.1	105
745	Statins and Carotid Intima-Media Thickness Reduction: An Up-to-Date Review. <i>Current Medicinal Chemistry</i> , 2009, 16, 1799-1805.	1.2	23
746	Evaluation of Lipid Profiles and the Use of Omega-3 Essential Fatty Acid in Professional Football Players. <i>Sports Health</i> , 2009, 1, 21-30.	1.3	16

#	ARTICLE	IF	CITATIONS
747	Tracking and determinants of LDL particle size in healthy children from 7 to 11 years of age: the STRIP Study. <i>European Journal of Pediatrics</i> , 2009, 168, 531-539.	1.3	9
748	The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance?. <i>Acta Diabetologica</i> , 2009, 46, 1-11.	1.2	27
749	The HMG-CoA Reductase Gene and Lipid and Lipoprotein Levels: the Multi-Ethnic Study of Atherosclerosis. <i>Lipids</i> , 2009, 44, 733-743.	0.7	18
750	Molecular structure of low density lipoprotein: current status and future challenges. <i>European Biophysics Journal</i> , 2009, 38, 145-158.	1.2	97
751	Small, dense low-density lipoproteins (LDL) are predictors of cardiovascular and cerebrovascular events in subjects with the metabolic syndrome. <i>Clinical Endocrinology</i> , 2009, 70, 870-875.	1.2	94
752	Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL profiles. <i>European Journal of Clinical Investigation</i> , 2009, 39, 463-470.	1.7	23
753	Reversal of Small, Dense LDL Subclass Phenotype by Normalization of Adiposity. <i>Obesity</i> , 2009, 17, 1768-1775.	1.5	36
754	Targeting triglycerides in secondary prevention: should we bother?. <i>International Journal of Clinical Practice</i> , 2009, 63, 15-18.	0.8	3
755	Lipid modification in type 2 diabetes: the role of LDL and HDL. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 681-685.	1.0	84
756	Application of poly(dimethylsiloxane)/glass microchip for fast electrophoretic separation of serum small, dense low-density lipoprotein. <i>Journal of Chromatography A</i> , 2009, 1216, 6343-6347.	1.8	14
757	Apolipoprotein B versus LDL-cholesterol: Association with other risk factors for atherosclerosis. <i>Clinical Biochemistry</i> , 2009, 42, 1246-1251.	0.8	17
758	Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome. <i>Diabetes Care</i> , 2009, 32, 493-498.	4.3	488
759	Lipid disorders in type 1 diabetes. <i>Diabetes and Metabolism</i> , 2009, 35, 353-360.	1.4	125
760	The predictive role of atherogenic dyslipidemia in subjects with non-coronary atherosclerosis. <i>Clinica Chimica Acta</i> , 2009, 406, 36-40.	0.5	18
761	Phosphoinositide cycle gene polymorphisms affect the plasma lipid profile in the Quebec Family Study. <i>Molecular Genetics and Metabolism</i> , 2009, 97, 149-154.	0.5	24
762	Pediatric triglycerides predict cardiovascular disease events in the fourth to fifth decade of life. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 1277-1284.	1.5	52
763	Atherogenic dyslipidemia and oxidative stress: a new look. <i>Translational Research</i> , 2009, 153, 217-223.	2.2	105
764	Lipid disorders in type 2 diabetes. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2009, 56, 43-45.	0.8	5

#	ARTICLE	IF	CITATIONS
765	Small and dense LDL in familial combined hyperlipidemia and N291S polymorphism of the lipoprotein lipase gene. <i>Lipids in Health and Disease</i> , 2009, 8, 12.	1.2	9
766	Stearate-Enriched Plant Sterol Esters Lower Serum LDL Cholesterol Concentration in Normo- and Hypercholesterolemic Adults. <i>Journal of Nutrition</i> , 2009, 139, 1445-1450.	1.3	39
767	Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals. <i>Atherosclerosis</i> , 2009, 202, 289-295.	0.4	71
768	Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis. <i>Atherosclerosis</i> , 2009, 202, 582-588.	0.4	58
769	Small dense low-density lipoprotein in familial combined hyperlipidemia: Independent of metabolic syndrome and related to history of cardiovascular events. <i>Atherosclerosis</i> , 2009, 203, 320-324.	0.4	21
770	Small dense LDL-cholesterol determined by a simple precipitation assay for screening familial combined hyperlipidemia. <i>Atherosclerosis</i> , 2009, 205, 603-607.	0.4	10
771	Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. <i>Atherosclerosis</i> , 2009, 207, 502-506.	0.4	63
772	Refining and expanding the role of small, dense low-density lipoproteins. <i>Atherosclerosis</i> , 2009, 207, 350-351.	0.4	1
773	Triglicéridos en ayunas y posprandiales, y su contribución al estudio del riesgo cardiometabólico. <i>Clínica E Investigación En Arteriosclerosis</i> , 2009, 21, 290-297.	0.4	0
774	Triglycerides as vascular risk factors: new epidemiologic insights. <i>Current Opinion in Cardiology</i> , 2009, 24, 345-350.	0.8	129
775	Lipoprotein glycation in atherogenesis. <i>Clinical Lipidology</i> , 2009, 4, 781-790.	0.4	12
776	Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2009, 15, 3446-3462.	0.9	7
777	Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD. <i>Current Cardiology Reviews</i> , 2010, 6, 112-118.	0.6	21
778	Lipoprotein subfractions and cardiovascular disease risk. <i>Current Opinion in Lipidology</i> , 2010, 21, 305-311.	1.2	216
779	Abnormalities in lipoprotein kinetics in Type 2 diabetes. <i>Clinical Lipidology</i> , 2010, 5, 277-289.	0.4	1
780	Atherogenic Dyslipidemia: Cardiovascular Risk and Dietary Intervention. <i>Lipids</i> , 2010, 45, 907-914.	0.7	251
781	Limited Effect of Dietary Saturated Fat on Plasma Saturated Fat in the Context of a Low Carbohydrate Diet. <i>Lipids</i> , 2010, 45, 947-962.	0.7	75
782	Ethnic differences in serum lipoproteins and their determinants in South African women. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 1341-1350.	1.5	69

#	ARTICLE	IF	CITATIONS
783	Predictive value of serum apolipoprotein B/LDL-cholesterol ratio in cardiometabolic risk: Population-based cohort study. <i>Clinical Biochemistry</i> , 2010, 43, 1381-1386.	0.8	18
784	Report of the international symposium: polycystic ovary syndrome: first Latin-American consensus. <i>International Journal of Clinical Practice</i> , 2010, 64, 544-557.	0.8	10
785	Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events. <i>European Journal of Clinical Investigation</i> , 2010, 40, 187-194.	1.7	17
786	Comparative effects of the leaves of <i>Gongronema latifolium</i> and <i>Telfaira occidentalis</i> incorporated diets on lipid profiles of rats.. <i>Global Journal of Pure and Applied Sciences</i> , 2010, 16, .	0.1	1
787	Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease. <i>Journal of Multidisciplinary Healthcare</i> , 2010, 3, 79.	1.1	7
788	Low HDL cholesterol is associated with increased atherogenic lipoproteins and insulin resistance in women classified with metabolic syndrome. <i>Nutrition Research and Practice</i> , 2010, 4, 492.	0.7	11
789	Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype. <i>Circulation</i> , 2010, 121, 1722-1734.	1.6	195
790	Non-LDL-related dyslipidaemia and coronary risk: a case-control study. <i>Diabetes and Vascular Disease Research</i> , 2010, 7, 204-212.	0.9	21
791	Cardiovascular Disease in Type 2 Diabetes From Population to Man to Mechanisms. <i>Diabetes Care</i> , 2010, 33, 442-449.	4.3	217
792	Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol Are Better Risk Markers for Coronary Artery Disease than Low-Density Lipoprotein Cholesterol in Hypertriglyceridemic Metabolic Syndrome Patients. <i>Metabolic Syndrome and Related Disorders</i> , 2010, 8, 515-522.	0.5	13
793	The effect of $\Delta$ insulin resistance and obesity on low-density lipoprotein particle size in children. <i>JCRPE Journal of Clinical Research in Pediatric Endocrinology</i> , 2010, 2, 63-66.	0.4	7
794	Prepregnancy Body Mass Index and Gestational Age-Dependent Changes in Lipid Levels During Pregnancy. <i>Obstetrics and Gynecology</i> , 2010, 116, 107-113.	1.2	59
795	PPAR- $\beta$ agonists, insulin resistance and dyslipidemia: not a simple relationship. <i>Clinical Lipidology</i> , 2010, 5, 509-525.	0.4	4
796	Clinical and genetic factors influencing cardiovascular risk in patients with familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2010, 5, 189-197.	0.4	7
797	Direct and Simple Fluorescence Detection Method for Oxidized Lipoproteins. <i>Analytical Chemistry</i> , 2010, 82, 1128-1132.	3.2	5
798	Unfavorable lipid profile in women with endometriosis. <i>Fertility and Sterility</i> , 2010, 93, 2433-2436.	0.5	84
799	Estimation of the low-density lipoprotein (LDL) subclass phenotype using a direct, automated assay of small dense LDL-cholesterol without sample pretreatment. <i>Clinica Chimica Acta</i> , 2010, 411, 1361-1366.	0.5	21
800	Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2038-2049.	1.8	831

#	ARTICLE	IF	CITATIONS
801	Developing computational model-based diagnostics to analyse clinical chemistry data. <i>Briefings in Bioinformatics</i> , 2010, 11, 403-416.	3.2	6
802	The Correlation between Lipids Ratio and Degree of Coronary Artery Stenosis. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011, 18, 53-56.	1.0	21
803	Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2011, 5, 483-492.	0.6	75
804	Development of a Homogeneous Assay for Measurement of Small Dense LDL Cholesterol. <i>Clinical Chemistry</i> , 2011, 57, 57-65.	1.5	136
805	Apolipoproteins: metabolic role and clinical biochemistry applications. <i>Annals of Clinical Biochemistry</i> , 2011, 48, 498-515.	0.8	164
806	Effects of Peroxisome Proliferator-Activated Receptors, Dietary Fat Intakes and Gene-Diet Interactions on Peak Particle Diameters of Low-Density Lipoproteins. <i>Journal of Nutrigenetics and Nutrigenomics</i> , 2011, 4, 36-48.	1.8	24
807	Impact of Obesity on Cardiovascular Disease. <i>Medical Clinics of North America</i> , 2011, 95, 919-937.	1.1	160
808	Evaluation of a new homogenous method for detection of small dense LDL cholesterol: Comparison with the LDL cholesterol profile obtained by density gradient ultracentrifugation. <i>Clinica Chimica Acta</i> , 2011, 412, 556-561.	0.5	29
809	Apolipoprotein A-I, apolipoprotein B, and apolipoprotein B/apolipoprotein A-I ratio: Reference intervals compared with values in different pathophysiological conditions from the FINRISK 2007 study. <i>Clinica Chimica Acta</i> , 2011, 412, 1146-1150.	0.5	10
811	Prevalence of Metabolic Syndrome and its Components in Patients With Acute Coronary Syndrome. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2011, 64, 579-586.	0.4	20
812	A Higher Burden of Small Low-density Lipoprotein Particles is Associated with Profound Changes in the Free Androgen Index in Male Adolescents. <i>Journal of Korean Medical Science</i> , 2011, 26, 534.	1.1	2
813	Homocysteine and inflammatory biomarkers plasma levels, and severity of acute coronary syndrome. <i>Annales De Biologie Clinique</i> , 2011, 69, 175-180.	0.2	8
814	Smaller Mean LDL Particle Size and Higher Proportion of Small Dense LDL in Korean Type 2 Diabetic Patients. <i>Diabetes and Metabolism Journal</i> , 2011, 35, 536.	1.8	16
815	Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus. <i>Vascular Health and Risk Management</i> , 2011, 7, 75.	1.0	24
816	Energy Substrate Partitioning and Efficiency in Individuals With Atherogenic Lipoprotein Phenotype. <i>Obesity</i> , 2011, 19, 1360-1365.	1.5	3
817	Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 78-85.	1.5	42
818	Diagnostic markers based on a computational model of lipoprotein metabolism. <i>Journal of Clinical Bioinformatics</i> , 2011, 1, 29.	1.2	10
819	Low-density lipoprotein density determination by electric conductivity. <i>Analytical Biochemistry</i> , 2011, 417, 283-285.	1.1	2

#	ARTICLE	IF	CITATIONS
820	Simultaneous Determination of High-Density Lipoprotein, Very Low-Density Lipoprotein and Low-Density Lipoprotein Subclass in Human Serum by Microchip CE. <i>Chromatographia</i> , 2011, 74, 799-805.	0.7	11
821	Glycated hemoglobin, dyslipidemia and risk of atherosclerosis in type 1 diabetic patients. <i>International Journal of Diabetes in Developing Countries</i> , 2011, 31, 18-21.	0.3	3
822	Effects of Diet on High-Density Lipoprotein Cholesterol. <i>Current Atherosclerosis Reports</i> , 2011, 13, 453-460.	2.0	44
823	Effect of ketogenic mediterranean diet with phytoextracts and low carbohydrates/high-protein meals on weight, cardiovascular risk factors, body composition and diet compliance in Italian council employees. <i>Nutrition Journal</i> , 2011, 10, 112.	1.5	63
824	Small dense LDL particles - a predictor of coronary artery disease evaluated by invasive and CT-based techniques: a case-control study. <i>Lipids in Health and Disease</i> , 2011, 10, 21.	1.2	34
825	Influence of HSA and IgG on LDL oxidation studied by size-exclusion chromatography and phospholipid profiling using MALDI tandem-mass spectrometry. <i>Chemistry and Physics of Lipids</i> , 2011, 164, 563-572.	1.5	4
826	Adiponectin Is Associated with Favorable Lipoprotein Profile, Independent of BMI and Insulin Resistance, in Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1549-1554.	1.8	41
827	Clinical applications of advanced lipoprotein testing in diabetes mellitus. <i>Clinical Lipidology</i> , 2011, 6, 371-387.	0.4	14
828	Effects of Insulin Sensitivity, Body Composition, and Fitness on Lipoprotein Particle Sizes and Concentrations Determined by Nuclear Magnetic Resonance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E713-E718.	1.8	12
829	A Lutein-Enriched Diet Prevents Cholesterol Accumulation and Decreases Oxidized LDL and Inflammatory Cytokines in the Aorta of Guinea Pigs. <i>Journal of Nutrition</i> , 2011, 141, 1458-1463.	1.3	87
830	Recent Advances in the Treatment of Atherogenic Dyslipidemia in Type 2 Diabetes Mellitus. <i>Kidney and Blood Pressure Research</i> , 2011, 34, 209-217.	0.9	15
831	Hyperlipidemia in Primary Care. , 2011, , .		2
832	Hypertriglyceridemia. , 2011, , 141-158.		0
833	Computational models for analyzing lipoprotein profiles. <i>Clinical Lipidology</i> , 2011, 6, 25-33.	0.4	5
834	Novel Cardiac-Specific Biomarkers and the Cardiovascular Continuum. <i>Biomarker Insights</i> , 2012, 7, BMI.S9536.	1.0	34
836	Insulin Resistance and Polycystic Ovary Syndrome Through Life. <i>Current Pharmaceutical Design</i> , 2012, 18, 5569-5576.	0.9	40
837	Lipid and Lipoprotein Biomarkers and the Risk of Ischemic Stroke in Postmenopausal Women. <i>Stroke</i> , 2012, 43, 958-966.	1.0	52
839	High disaccharide intake associates with atherogenic lipoprotein profile. <i>British Journal of Nutrition</i> , 2012, 107, 1062-1069.	1.2	17

#	ARTICLE	IF	CITATIONS
840	Association of hypertension with small, dense low-density lipoprotein in patients without metabolic syndrome. <i>Journal of Human Hypertension</i> , 2012, 26, 670-676.	1.0	14
841	Adiponectin and sE-selectin Concentrations in Relation to Inflammation in Obese Type 2 Diabetic Patients With Coronary Heart Disease. <i>Angiology</i> , 2012, 63, 96-102.	0.8	11
842	Elevated Proportion of Small, Dense Low-Density Lipoprotein Particles and Lower Adiponectin Blood Levels Predict Early Structural Valve Degeneration of Bioprostheses. <i>Cardiology</i> , 2012, 121, 20-26.	0.6	12
843	Early-onset type 2 diabetes: higher burden of atherogenic apolipoprotein particles during statin treatment. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 973-980.	0.2	7
844	Naringin Ameliorates Atherogenic Dyslipidemia but not Hyperglycemia in Rats With Type 1 Diabetes. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 59, 133-141.	0.8	38
845	Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients. <i>Antiviral Therapy</i> , 2012, 17, 855-860.	0.6	6
846	Insulin Resistance and Coronary Heart Disease in Nondiabetic Individuals. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 1754-1759.	1.1	167
847	Risk of coronary heart disease is associated with triglycerides and high-density lipoprotein cholesterol in women and non-high-density lipoprotein cholesterol in men. <i>Journal of Clinical Lipidology</i> , 2012, 6, 374-381.	0.6	29
848	Treatment options for the management of hypertriglyceridemia: Strategies based on the best-available evidence. <i>Journal of Clinical Lipidology</i> , 2012, 6, 413-426.	0.6	74
850	American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. <i>Endocrine Practice</i> , 2012, 18, 1-78.	1.1	386
851	Retention of atherogenic lipoproteins in the artery wall and its role in atherogenesis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 1-7.	1.1	92
852	Physical activity and postprandial lipidemia: Are energy expenditure and lipoprotein lipase activity the real modulators of the positive effect?. <i>Progress in Lipid Research</i> , 2012, 51, 11-22.	5.3	68
853	Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2969-2989.	1.8	641
854	Serum triglycerides and risk of cardiovascular disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2012, 1821, 867-875.	1.2	122
855	The characteristics of remnant lipoproteins in the fasting and postprandial plasma. <i>Clinica Chimica Acta</i> , 2012, 413, 1077-1086.	0.5	33
856	Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. <i>Cardiovascular Diabetology</i> , 2012, 11, 125.	2.7	128
858	Serum Small Dense Low-density Lipoprotein Concentrations are Elevated in Patients with Significant Coronary Artery Stenosis and are Related to Features of the Metabolic Syndrome. <i>Lipids</i> , 2012, 47, 963-972.	0.7	10
859	Cardiovascular Risk in Children and Adolescents with Type 1 and Type 2 Diabetes Mellitus. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 591-600.	0.8	10

#	ARTICLE	IF	CITATIONS
861	Biochemical Basis and Clinical Consequences of Glucolipototoxicity. <i>Heart Failure Clinics</i> , 2012, 8, 501-511.	1.0	6
862	Application of a modified precipitation method for the measurement of small dense LDL-cholesterol (sd-LDL-C) in a population in southern Brazil. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1649-56.	1.4	8
863	Clustering by Plasma Lipoprotein Profile Reveals Two Distinct Subgroups with Positive Lipid Response to Fenofibrate Therapy. <i>PLoS ONE</i> , 2012, 7, e38072.	1.1	30
864	Dyslipidemia: Genetics and Role in the Metabolic Syndrome. , 2012, , .		0
865	Associations between Small Dense LDL, HDL Subfractions (HDL2, HDL3) and Risk of Atherosclerosis in Japanese-Americans. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 444-452.	0.9	59
866	The Importance of Lipid and Lipoprote in Ratios in Interpretations of Hyperlipidaemia of Pregnancy. , 0, , .		2
867	Higher levels of serum triglyceride and dietary carbohydrate intake are associated with smaller LDL particle size in healthy Korean women. <i>Nutrition Research and Practice</i> , 2012, 6, 120.	0.7	6
868	Low density lipoprotein size in relation to carotid intima-media thickness in coronary artery disease. <i>Bratislava Medical Journal</i> , 2012, 113, 87-91.	0.4	2
869	How Do Elevated Triglycerides and Low HDL-Cholesterol Affect Inflammation and Atherothrombosis?. <i>Current Cardiology Reports</i> , 2013, 15, 400.	1.3	142
870	Impact of low-density lipoprotein cholesterol on cardiovascular outcomes in people with type 2 diabetes: A meta-analysis of prospective cohort studies. <i>Diabetes Research and Clinical Practice</i> , 2013, 102, 65-75.	1.1	36
871	Lipides et diabÃ©te de type 1. <i>Medecine Des Maladies Metaboliques</i> , 2013, 7, 437-442.	0.1	1
872	Hypothesis driven single nucleotide polymorphism search (HyDn-SNP-S). <i>DNA Repair</i> , 2013, 12, 733-740.	1.3	11
873	Pattern and predictors of dyslipidemia in patients with type 2 diabetes mellitus. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2013, 7, 95-100.	1.8	19
874	The nuances of atherogenic dyslipidemia in diabetes: Focus on triglycerides and current management strategies. <i>Indian Heart Journal</i> , 2013, 65, 683-690.	0.2	10
875	Diabetes mellitus, but not small dense low-density lipoprotein, is predictive of cardiovascular disease: A Korean community-based prospective cohort study. <i>Journal of Diabetes Investigation</i> , 2013, 4, 546-551.	1.1	5
876	Relationship between Icodextrin use and decreased level of small low-density lipoprotein cholesterol fractioned by high-performance gel permeation chromatography. <i>BMC Nephrology</i> , 2013, 14, 234.	0.8	3
877	The association of very-low-density lipoprotein with ankle-brachial index in peritoneal dialysis patients with controlled serum low-density lipoprotein cholesterol level. <i>BMC Nephrology</i> , 2013, 14, 212.	0.8	6
878	Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study. <i>Journal of Inherited Metabolic Disease</i> , 2013, 36, 555-563.	1.7	10

#	ARTICLE	IF	CITATIONS
879	Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2013, 7, 304-383.	0.6	346
880	What have we learnt about high-density lipoprotein cholesterol measurements during 32years? Experiences in Finland 1980â€“2012. <i>Clinica Chimica Acta</i> , 2013, 415, 118-123.	0.5	13
881	Pathophysiology of Human Visceral Obesity: An Update. <i>Physiological Reviews</i> , 2013, 93, 359-404.	13.1	1,751
882	Effect of fish oil supplementation on serum triglycerides, LDL cholesterol and LDL subfractions in hypertriglyceridemic adults. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 350-357.	1.1	31
883	Determinants and clinical significance of plasma oxidized LDLs in older individuals. A 9 years follow-up study. <i>Atherosclerosis</i> , 2013, 226, 201-207.	0.4	25
884	Using new cut-off for lipidic parameters to predict development of affected arteries in patients with acute coronary syndrome. <i>Immuno-Analyse Et Biologie Specialisee</i> , 2013, 28, 373-377.	0.0	0
885	Association between small dense LDL and early atherosclerosis in a sample of menopausal women. <i>Clinica Chimica Acta</i> , 2013, 426, 1-5.	0.5	30
886	Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention. <i>BMC Neurology</i> , 2013, 13, 1.	0.8	87
888	Advanced oxidative and glycoxidative protein damage markers in the elderly with type 2 diabetes. <i>Journal of Proteomics</i> , 2013, 92, 313-322.	1.2	67
889	Hypolipidemic and antioxidant activities of thymoquinone and limonene in atherogenic suspension fed rats. <i>Food Chemistry</i> , 2013, 138, 1116-1124.	4.2	90
890	Dietary lipid modification for mild and severe dyslipidaemias. <i>Proceedings of the Nutrition Society</i> , 2013, 72, 337-341.	0.4	14
891	Serum uric acid: Marker for atherosclerosis as it is positively associated with atherogenic index of plasma. <i>Archives of Physiology and Biochemistry</i> , 2013, 119, 27-31.	1.0	28
892	CIDE-A gene expression in patients with abdominal obesity and LDL hyperlipoproteinemia qualified for surgical revascularization in chronic limb ischemia. <i>Polski Przegląd Chirurgiczny</i> , 2013, 85, 644-8.	0.2	3
893	Atherogenic dyslipidemia. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 969.	0.2	62
894	Separation of the principal HDL subclasses by iodixanol ultracentrifugation. <i>Journal of Lipid Research</i> , 2013, 54, 2273-2281.	2.0	3
895	Short-term estimation and application of biological variation of small dense low-density lipoproteins in healthy individuals. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 2167-72.	1.4	4
896	Increased Small Dense LDL and Decreased Paraoxonase Enzyme Activity Reveals Formation of an Atherogenic Risk in Streptozotocin-Induced Diabetic Guinea Pigs. <i>Journal of Diabetes Research</i> , 2013, 2013, 1-8.	1.0	7
897	Effects of the Addition of T'ai Chito a Dietary Weight Loss Program on Lipoprotein Atherogenicity in Obese Older Women. <i>Journal of Alternative and Complementary Medicine</i> , 2013, 19, 759-766.	2.1	20

#	ARTICLE	IF	CITATIONS
898	LDL Phenotype in Subjects with Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 571-575.	1.2	10
899	Classification of LDL Phenotypes by 4 Methods of Determining Lipoprotein Particle Size. <i>Journal of Investigative Medicine</i> , 2013, 61, 942-949.	0.7	21
900	Intercorrelations of lipoprotein subfractions and their covariation with lifestyle factors in healthy men. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2014, 54, 174-180.	0.6	10
901	Association of Serum 25-Hydroxyvitamin D with Lifestyle Factors and Metabolic and Cardiovascular Disease Markers: Population-Based Cross-Sectional Study (FIN-D2D). <i>PLoS ONE</i> , 2014, 9, e100235.	1.1	29
902	Serum Lipid Profiles, Lipid Ratios and Chronic Kidney Disease in a Chinese Population. <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 7622-7635.	1.2	17
903	Effects of Dietary Macronutrients on Plasma Lipid Levels and the Consequence for Cardiovascular Disease. <i>Journal of Cardiovascular Development and Disease</i> , 2014, 1, 201-213.	0.8	14
904	Study the Small and Dense Lipoprotein Levels (LDLsd) in Coronary Artery Disease. <i>Journal of Cardiovascular Diseases &amp; Diagnosis</i> , 2014, 02, .	0.0	0
905	Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia. <i>Clinical Lipidology</i> , 2014, 9, 149-161.	0.4	4
906	Prevalence and pattern of lipid disorders in Saudi patients with angiographically documented coronary artery disease. <i>Journal of Family and Community Medicine</i> , 2014, 21, 166.	0.5	7
907	Small dense low-density lipoprotein as a potential risk factor of nephropathy in type 2 diabetes mellitus. <i>Indian Journal of Endocrinology and Metabolism</i> , 2014, 18, 94.	0.2	9
908	Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?. <i>Indian Journal of Endocrinology and Metabolism</i> , 2014, 18, 283.	0.2	14
909	An <i>In Vitro</i> and Molecular Informatics Study to Evaluate the Antioxidative and $\beta$ -hydroxy $\beta$ -methylglutaryl-CoA Reductase Inhibitory Property of <i>Ficus virens</i> Ait. <i>Phytotherapy Research</i> , 2014, 28, 899-908.	2.8	21
910	A moderate-fat diet containing pistachios improves emerging markers of cardiometabolic syndrome in healthy adults with elevated LDL levels. <i>British Journal of Nutrition</i> , 2014, 112, 744-752.	1.2	39
911	The effects of treatment on lipoprotein subfractions evaluated by polyacrylamide gel electrophoresis in patients with autoimmune hypothyroidism and hyperthyroidism. <i>Lipids in Health and Disease</i> , 2014, 13, 158.	1.2	18
912	Potential implications of the choice among three alternative treatment targets for apolipoprotein B100 in the management of patients with type 2 diabetes and chronic kidney disease. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 53-59.	0.9	2
913	Simvastatin/fenofibrate combination in the treatment of dyslipidemia: current evidence. <i>Research and Reports in Endocrine Disorders</i> , 0, , 1.	0.4	0
914	Non-High-Density Lipoprotein Cholesterol and Coronary Artery Calcium Progression in a Multiethnic US Population. <i>American Journal of Cardiology</i> , 2014, 113, 471-474.	0.7	7
915	Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin-Resistant Diabetes. <i>Contemporary Diabetes</i> , 2014, , 11-40.	0.0	1

#	ARTICLE	IF	CITATIONS
916	Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients. <i>Contemporary Diabetes</i> , 2014, , 373-398.	0.0	0
917	Serum lipid concentrations among persons with spinal cord injury – A systematic review and meta-analysis of the literature. <i>Atherosclerosis</i> , 2014, 232, 305-312.	0.4	53
918	Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. <i>Cardiovascular risk perception. Clínica e Investigación en Arteriosclerosis</i> , 2014, 26, 274-284.	0.4	16
919	All Low-Density Lipoprotein Particles Are Not Created Equal. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 959-961.	1.1	44
920	Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1069-1077.	1.1	386
921	Microchip-based human serum atherogenic lipoprotein profile analysis. <i>Analytical Biochemistry</i> , 2014, 467, 75-83.	1.1	5
922	Statins in chronic kidney disease and kidney transplantation. <i>Pharmacological Research</i> , 2014, 88, 62-73.	3.1	22
923	Development of a low-cost, high-throughput native polyacrylamide gel electrophoresis (N-PAGE) protocol for lipoprotein sub-fractionation using Quality by Design approach. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 92, 119-126.	1.4	4
924	Effects of apolipoprotein E genotype on serum lipids in obstructive sleep apnoea. <i>European Respiratory Journal</i> , 2014, 43, 1097-1105.	3.1	14
925	Add-on Ezetimibe Reduces Small Dense Low-Density Lipoprotein Cholesterol Levels Without Affecting Absorption of Eicosapentaenoic Acid in Patients with Coronary Artery Disease: A Pilot Study. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 387-392.	1.0	5
926	Prevalence of atherogenic dyslipidemia: Association with risk factors and cardiovascular risk in Spanish working population. "ICARIA" study. <i>Atherosclerosis</i> , 2014, 235, 562-569.	0.4	26
927	The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 369-385.	2.2	32
928	Treatment options for hypertriglyceridemia: From risk reduction to pancreatitis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 423-437.	2.2	38
929	Phytochemicals and Immune Function. , 2014, , 79-96.		0
930	Apolipoprotein B as an independent predictor of arterial stiffness in systemic lupus erythematosus patients. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 447-451.	0.9	11
931	The Assessment of the Atherogenic Lipoprotein Profile in Cardiovascular Diseases by Lipoprint System Analysis. , 2015, , .		1
932	Complications and challenges associated with polycystic ovary syndrome: current perspectives. <i>International Journal of Women's Health</i> , 2015, 7, 745.	1.1	153
933	Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2015, 8, 189.	1.1	41

#	ARTICLE	IF	CITATIONS
934	Hypertriglyceridemia is a Major Factor Associated With Elevated Levels of Small Dense LDL Cholesterol in Patients With Metabolic Syndrome. <i>Annals of Laboratory Medicine</i> , 2015, 35, 586-594.	1.2	27
935	Flaxseed oil intake reduces serum small dense low-density lipoprotein concentrations in Japanese men: a randomized, double blind, crossover study. <i>Nutrition Journal</i> , 2015, 14, 39.	1.5	39
936	Type 1 Diabetes Mellitus and Dyslipidemia. <i>Contemporary Endocrinology</i> , 2015, , 115-135.	0.3	2
937	Effects of Armolipid Plus on small dense LDL particles in a sample of patients affected by familial combined hyperlipidemia. <i>Clinical Lipidology</i> , 2015, 10, 475-480.	0.4	16
938	Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9. <i>Journal of Clinical Lipidology</i> , 2015, 9, 511-518.e5.	0.6	5
939	Hypertriglyceridemia in the Genomic Era: A New Paradigm. <i>Endocrine Reviews</i> , 2015, 36, 131-147.	8.9	118
940	New insights into the pathophysiology of dyslipidemia in type 2 diabetes. <i>Atherosclerosis</i> , 2015, 239, 483-495.	0.4	314
941	Small-dense LDL/large-buoyant LDL ratio associates with the metabolic syndrome. <i>Clinical Biochemistry</i> , 2015, 48, 495-502.	0.8	11
942	Plasma proteomics to identify biomarkers – application to cardiovascular diseases. <i>Translational Proteomics</i> , 2015, 7, 40-48.	1.2	44
943	Diabetes to cardiovascular disease: Is depression the potential missing link?. <i>Medical Hypotheses</i> , 2015, 84, 370-378.	0.8	13
944	Effect of a Moderate Fat Diet With and Without Avocados on Lipoprotein Particle Number, Size and Subclasses in Overweight and Obese Adults: A Randomized, Controlled Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e001355.	1.6	89
945	Associations of small dense low-density lipoprotein and adiponectin with complications of type 2 diabetes. <i>Endocrine Research</i> , 2015, 40, 14-19.	0.6	4
946	Observational Study of Effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes. <i>Scientific Reports</i> , 2015, 5, 7706.	1.6	24
947	Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk. <i>Clinical Science</i> , 2015, 128, 877-882.	1.8	25
948	Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 213-219.	1.0	15
949	Atherosclerosis, Introduction and Pathophysiology. , 2015, , 527-546.		1
950	The protective effect of vitamin E against prenatal and early postnatal ethanol treatment-induced heart abnormality in rats: A 3-month follow-up study. <i>International Immunopharmacology</i> , 2015, 26, 72-79.	1.7	29
951	Translational value of animal models of obesity – Focus on dogs and cats. <i>European Journal of Pharmacology</i> , 2015, 759, 240-252.	1.7	36

#	ARTICLE	IF	CITATIONS
952	Elevated Triglycerides, Atherosclerosis and Adverse Clinical Events. , 2015, , 55-67.		0
953	Predictors of high-risk coronary artery disease detected by coronary computed tomographic angiography in diabetic patients without known coronary artery disease. International Journal of Cardiology, 2015, 201, 324-325.	0.8	0
954	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrateâ€“statin combination therapy. Atherosclerosis Supplements, 2015, 19, 1-12.	1.2	66
955	Insulin resistance predicts early cardiovascular morbidity in men without diabetes mellitus, with effect modification by physical activity. European Journal of Preventive Cardiology, 2015, 22, 940-949.	0.8	18
957	Hepatitis C virus G1b infection decreases the number of small low-density lipoprotein particles. World Journal of Gastroenterology, 2016, 22, 6716.	1.4	2
958	Potential role of apolipoprotein B/A1 ration in obese and non-obese female patients of coronary artery disease. Asian Journal of Medical Sciences, 2016, 7, 18-22.	0.0	0
959	Effects of Small Dense LDL in Diabetic Nephropathy in Females with Type 2 Diabetes Mellitus. Journal of Lipid and Atherosclerosis, 2016, 5, 11.	1.1	1
960	Dyslipidemia and Food Security in Low-Income US Adolescents: National Health and Nutrition Examination Survey, 2003â€“2010. Preventing Chronic Disease, 2016, 13, E22.	1.7	16
961	Nutrition, Diet Quality, and Cardiovascular Health. , 2016, , 315-330.		4
962	Effects of a sweetpotato protein digest on lipid metabolism in mice administered a high-fat diet. Heliyon, 2016, 2, e00201.	1.4	5
963	Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. Journal of Diabetes and Its Complications, 2016, 30, 1365-1370.	1.2	10
964	The association of circulating microRNA-30c with atherogenic lipoprotein subfractions and composition. Clinica Chimica Acta, 2016, 462, 135-139.	0.5	1
965	Triglycerides (TG) to High-Density Lipoprotein (HDL-c) Ratio (TG/HDL-c Ratio) as a Marker of Cardiometabolic Risk. , 2016, , 219-234.		1
966	Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. Diabetes, 2016, 65, 1767-1778.	0.3	155
967	In silico modeling of the dynamics of low density lipoprotein composition via a single plasma sample. Journal of Lipid Research, 2016, 57, 882-893.	2.0	4
968	Perioperative Anesthetic Care of the Obese Patient. , 0, , .		3
970	Genetics of Lipid Disorders. , 2016, , 159-193.		0
971	Atherosclerosis â€” do we know enough already to prevent it?. Current Opinion in Pharmacology, 2016, 27, 92-102.	1.7	33

#	ARTICLE	IF	CITATIONS
972	Switching from atorvastatin to rosuvastatin lowers small, dense low-density lipoprotein cholesterol levels in Japanese hypercholesterolemic patients with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2016, 111, 66-73.	1.1	5
973	American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. <i>Endocrine Practice</i> , 2017, 23, 1-87.	1.1	766
974	Advanced lipoprotein testing for cardiovascular diseases risk assessment: a review of the novel approaches in lipoprotein profiling. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1453-1464.	1.4	24
975	Atherogenic Dyslipidemia in Latin America: Prevalence, causes and treatment. <i>International Journal of Cardiology</i> , 2017, 243, 516-522.	0.8	37
976	Additive Antiatherogenic Effects of CETP rs708272 on Serum LDL Subfraction Levels in Patients with CHD Under Statin Therapy. <i>Biochemical Genetics</i> , 2017, 55, 168-182.	0.8	3
977	Atherogenic Dyslipidemia Remission 1 Year After Bariatric Surgery. <i>Obesity Surgery</i> , 2017, 27, 1548-1553.	1.1	10
978	Management of Lipids in Patients with Diabetes. <i>Nursing Clinics of North America</i> , 2017, 52, 605-619.	0.7	9
979	On-Chip Lipid Extraction Using Superabsorbent Polymers for Mass Spectrometry. <i>Analytical Chemistry</i> , 2017, 89, 13365-13373.	3.2	15
980	Novel Risk Stratification Assays for Acute Coronary Syndrome. <i>Current Cardiology Reports</i> , 2017, 19, 69.	1.3	4
981	Ginger extract mitigates ethanol-induced changes of alpha and beta $\alpha$ myosin heavy chain isoforms gene expression and oxidative stress in the heart of male wistar rats. <i>DNA Repair</i> , 2017, 57, 45-49.	1.3	12
982	Method for estimating high sdLDL-C by measuring triglyceride and apolipoprotein B levels. <i>Lipids in Health and Disease</i> , 2017, 16, 21.	1.2	34
983	Impact of menopause and diabetes on atherogenic lipid profile: is it worth to analyse lipoprotein subfractions to assess cardiovascular risk in women?. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 22.	1.2	46
984	A pooled analysis of the association of isolated low levels of high-density lipoprotein cholesterol with cardiovascular mortality in Japan. <i>European Journal of Epidemiology</i> , 2017, 32, 547-557.	2.5	20
985	Using the VAP lipid panel for the detection, evaluation, and treatment of patients at risk for CAD. <i>Frontiers in Laboratory Medicine</i> , 2017, 1, 182-185.	1.7	0
986	Risk factor profile of coronary artery disease in black South Africans. <i>SA Heart Journal</i> , 2017, 7, .	0.0	0
987	High Dietary Fructose Intake on Cardiovascular Disease Related Parameters in Growing Rats. <i>Nutrients</i> , 2017, 9, 11.	1.7	39
988	The effect of nandrolone treatment with and without enforced swimming on histological and biochemical changes in the heart and coronary artery of male rats. <i>Anatolian Journal of Cardiology</i> , 2017, 17, 176-183.	0.5	11
989	Elevation of small, dense low density lipoprotein cholesterol—a possible antecedent of atherogenic lipoprotein phenotype in type 2 diabetes patients in Jos, North-Central Nigeria. <i>BMC Clinical Pathology</i> , 2017, 17, 26.	1.8	4

#	ARTICLE	IF	CITATIONS
990	Reference values assessment in a Mediterranean population for small dense low-density lipoprotein concentration isolated by an optimized precipitation method. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 201-207.	1.0	8
991	Treating Dyslipidemia in Type 2 Diabetes. <i>Cardiology Clinics</i> , 2018, 36, 233-239.	0.9	11
992	Lipid Disorders in Obesity. , 2018, , 99-108.		3
993	ENHO, RXRA, and LXRA polymorphisms and dyslipidaemia, related comorbidities and survival in haemodialysis patients. <i>BMC Medical Genetics</i> , 2018, 19, 194.	2.1	8
994	Cardiovascular risk profile of patients with atherogenic dyslipidemia in middle age Lithuanian population. <i>Lipids in Health and Disease</i> , 2018, 17, 208.	1.2	9
995	Atherosclerotic Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2018, 138, e1-e34.	1.6	316
996	Low-Density Lipoprotein Triglycerides. <i>Journal of the American College of Cardiology</i> , 2018, 72, 170-172.	1.2	10
997	Diabetes and Dislipidemia. <i>Endocrinology</i> , 2018, , 1-20.	0.1	0
998	Pathophysiology of Diabetic Dyslipidemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 771-782.	0.9	271
999	Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. <i>Clinical Cardiology</i> , 2018, 41, 1281-1288.	0.7	151
1000	Dietary carbohydrate restriction improves metabolic syndrome independent of weight loss. <i>JCI Insight</i> , 2019, 4, .	2.3	141
1001	Effect of berries/apple mixed juice consumption on the positive modulation of human lipid profile. <i>Journal of Functional Foods</i> , 2019, 60, 103417.	1.6	4
1002	An update on metabolic syndrome: Metabolic risk markers and adipokines in the development of metabolic syndrome. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 2409-2417.	1.8	74
1003	A randomized, controlled trial on the effects of almonds on lipoprotein response to a higher carbohydrate, lower fat diet in men and women with abdominal adiposity. <i>Lipids in Health and Disease</i> , 2019, 18, 83.	1.2	10
1004	Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial. <i>Lipids in Health and Disease</i> , 2019, 18, 66.	1.2	9
1005	Diabetes and Dyslipidemia. <i>Endocrinology</i> , 2019, , 1-20.	0.1	0
1006	Association of paraoxonase-1 L55M and Q192R polymorphisms with PCOS risk and potential risk factors for atherosclerosis. <i>Biomarkers in Medicine</i> , 2019, 13, 279-289.	0.6	4
1007	Prevalence and pattern of dyslipidemia in patients with type 2 diabetes mellitus in Zaria, Northwestern Nigeria. <i>Pan African Medical Journal</i> , 2019, 34, 123.	0.3	14

#	ARTICLE	IF	CITATIONS
1008	Small Dense Low-Density Lipoprotein: Biomarker or Potential Drug Target?. Annals of the National Academy of Medical Sciences (India), 2019, 55, 092-097.	0.2	0
1009	Exercise and Cardiovascular Risk among Masters Athletes with Type 2 Diabetes. Current Diabetes Reports, 2019, 19, 127.	1.7	3
1010	Cannabis effects on lipoproteins. Current Opinion in Lipidology, 2019, 30, 140-146.	1.2	15
1011	Lipoprotein Sub-Fractions by Ion-Mobility Analysis and Its Association with Subclinical Coronary Atherosclerosis in High-Risk Individuals. Journal of Atherosclerosis and Thrombosis, 2019, 26, 50-63.	0.9	16
1012	Metabolic disorders and inflammation are associated with familial combined hyperlipemia. Clinica Chimica Acta, 2019, 490, 194-199.	0.5	10
1013	Serum apolipoprotein B is associated with increased risk of metabolic syndrome among middle-aged and elderly Chinese: A cross-sectional and prospective cohort study. Journal of Diabetes, 2019, 11, 752-760.	0.8	11
1014	Utility of apolipoprotein measurements in predicting incident type 2 diabetes: A Chinese cohort study. Journal of the Formosan Medical Association, 2020, 119, 51-58.	0.8	12
1015	High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?. American Journal of Cardiovascular Drugs, 2020, 20, 11-18.	1.0	0
1016	Evaluation of small dense low-density lipoprotein concentration for predicting the risk of acute coronary syndrome in Chinese population. Journal of Clinical Laboratory Analysis, 2020, 34, e23085.	0.9	4
1017	Exercise Training Adaptations in Metabolic Syndrome Individuals on Chronic Statin Treatment. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1695-e1704.	1.8	9
1018	Metabolic Syndrome or Insulin Resistance: Evolution, Controversies and Association With Cardiovascular Disease Risk. Indian Journal of Clinical Cardiology, 2020, 1, 77-85.	0.3	6
1019	Effect of low-carbohydrate diets on cardiometabolic risk, insulin resistance, and metabolic syndrome. Current Opinion in Endocrinology, Diabetes and Obesity, 2020, 27, 301-307.	1.2	45
1020	Low plasma apolipoprotein E-rich high-density lipoprotein levels in patients with metabolic syndrome. Clinica Chimica Acta, 2020, 510, 531-536.	0.5	1
1021	The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study. American Journal of Preventive Cardiology, 2020, 4, 100097.	1.3	10
1023	Plasma lipids in patients with inflammatory bowel disease. Wiener Klinische Wochenschrift, 2020, 132, 283-294.	1.0	4
1024	Dyslipidaemias and their treatment in high complexity centres in Colombia. Clínica E Investigación En Arteriosclerosis (English Edition), 2020, 32, 101-110.	0.1	2
1025	Coronary and Peripheral Artery Plaques: Do Differences in Plaque Characteristics Translate to Differences in Lipid Management?. Journal of Investigative Medicine, 2020, 68, 1141-1151.	0.7	9
1026	Dyslipidemia in Type 1 Diabetes: A Masked Danger. Trends in Endocrinology and Metabolism, 2020, 31, 422-434.	3.1	64

#	ARTICLE	IF	CITATIONS
1027	Gender differences in LDL and HDL subfractions in atherogenic and nonatherogenic phenotypes. <i>Clinical Biochemistry</i> , 2020, 79, 9-13.	0.8	14
1028	A Randomized Study of the Effect of Replacing Sugar-Sweetened Soda by Reduced Fat Milk on Cardiometabolic Health in Male Adolescent Soda Drinkers. <i>Nutrients</i> , 2020, 12, 405.	1.7	14
1029	Toward reliable low-density lipoprotein ultrastructure prediction in clinical conditions: A small-angle X-ray scattering study on individuals with normal and high triglyceride serum levels. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 31, 102318.	1.7	4
1030	Lower LDL-cholesterol levels associated with increased inflammatory burden in patients with acute ST-segment elevation myocardial infarction. <i>Revista Da Associação Médica Brasileira</i> , 2021, 67, 224-229.	0.3	5
1031	Small Dense Low-Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study. <i>Journal of the American Heart Association</i> , 2021, 10, e019140.	1.6	88
1032	Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON. <i>Cardiovascular Diabetology</i> , 2021, 20, 94.	2.7	17
1033	Circulating microRNA-126 & 122 in patients with coronary artery disease: Correlation with small dense LDL. <i>Prostaglandins and Other Lipid Mediators</i> , 2021, 153, 106536.	1.0	13
1034	Hypolipidemic, Antioxidant and Cardioprotective Effects of the Aqueous Extract from <i>Scorzanera Undulata</i> Tubers in Streptozotocin-Induced Diabetic Rats. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2021, 19, 17-23.	0.4	2
1035	Long-term fasting improves lipoprotein-associated atherogenic risk in humans. <i>European Journal of Nutrition</i> , 2021, 60, 4031-4044.	1.8	19
1036	Niveles séricos de interleucina-6 en pacientes con diabetes tipo 2 y su correlación con el perfil lipídico. <i>Revista Digital De Postgrado</i> , 2021, 10, .	0.2	0
1037	The Aging Vasculature: Glucose Tolerance, Hypoglycemia and the Role of the Serum Response Factor. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 58.	0.8	4
1038	Effect of carbohydrate-restricted dietary interventions on LDL particle size and number in adults in the context of weight loss or weight maintenance: a systematic review and meta-analysis. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 1455-1466.	2.2	18
1039	Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis. <i>Virology Journal</i> , 2021, 18, 157.	1.4	53
1040	The effects of fat consumption on low-density lipoprotein particle size in healthy individuals: a narrative review. <i>Lipids in Health and Disease</i> , 2021, 20, 86.	1.2	10
1041	Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 28-43.	2.2	40
1042	Severe Hepatic Insulin Resistance Induces Vascular Dysfunction: Improvement by Liver-Specific Insulin Receptor Isoform A Gene Therapy in a Murine Diabetic Model. <i>Cells</i> , 2021, 10, 2035.	1.8	2
1043	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021, 42, 4791-4806.	1.0	303
1044	High-density lipoproteins. , 2021, , 487-514.		1

#	ARTICLE	IF	CITATIONS
1045	Lipids and atherosclerosis. , 2004, , 791-807.		2
1046	Pathophysiology of Atherosclerosis. , 2000, , 85-105.		7
1047	Phospholipase A2 Modification of Lipoproteins: Potential Effects on Atherogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2002, 507, 3-7.	0.8	10
1048	Syndrome X. , 1997, , 357-382.		6
1049	Ethnic Variation in Insulin Resistance and Risk of Type 2 Diabetes. , 1999, , 19-33.		4
1050	Obesity and Insulin Resistance. , 1999, , 51-81.		11
1051	Egg Composition vs CVD Risk. , 2008, , 155-167.		2
1052	Pathophysiology and Management of Dyslipidemias Associated with Insulin-Resistant States. <i>Contemporary Cardiology</i> , 2021, , 307-322.	0.0	3
1053	Besonderheiten im atherogenen Risikoprofil der KHK bei Frauen. , 2002, , 47-55.		1
1054	Atherogenic Dyslipidemia and the Metabolic Syndrome: Pathogenesis and Challenge of Therapy. <i>Medical Science Symposia Series</i> , 1996, , 237-247.	0.0	4
1056	A Metabolic Model for the Hypolipidemic and Antiatherogenic Effects of N-3 Fatty Acids: Effect of Omacor on Plasma Lipids. <i>Medical Science Symposia Series</i> , 1996, , 675-680.	0.0	1
1057	Metabolic Basis of the Atherogenic Lipoprotein Phenotype. <i>Medical Science Symposia Series</i> , 1995, , 289-294.	0.0	2
1058	Exercise and Coronary Heart Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1228, 169-179.	0.8	23
1059	LDL subclasses in IDDM patients: relation to diabetic nephropathy. <i>Diabetologia</i> , 1994, 37, 681-688.	2.9	1
1060	The fourth Musketeer ? from Alexandre Dumas to Claude Bernard. <i>Diabetologia</i> , 1995, 38, 3-13.	2.9	109
1061	Changes of lipolytic enzymes cluster with insulin resistance syndrome. <i>Diabetologia</i> , 1995, 38, 344-350.	2.9	11
1062	Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. <i>Diabetologia</i> , 1996, 39, 453-461.	2.9	13
1064	Causes for Concern and Opportunities for Enhanced Nutrition in the Modification of Dietary Carbohydrate Composition. , 1992, , 167-189.		1

#	ARTICLE	IF	CITATIONS
1065	The Contribution of Triglycerides and Triglyceride-Rich Lipoproteins to Atherosclerotic Cardiovascular Disease. , 2011, , 230-251.		1
1066	Las dislipidemias y su tratamiento en centros de alta complejidad en Colombia. Clínica E Investigaci3n En Arteriosclerosis, 2020, 32, 101-110.	0.4	3
1067	Properties of triglyceride-rich and cholesterol-rich lipoproteins in the remnant-like particle fraction of human blood plasma. Journal of Lipid Research, 2002, 43, 365-374.	2.0	25
1068	A rapid single-step centrifugation method for determination of HDL, LDL, and VLDL cholesterol, and TG, and identification of predominant LDL subclass. Journal of Lipid Research, 2002, 43, 335-343.	2.0	34
1069	Structure of apolipoprotein B-100 in low density lipoproteins. Journal of Lipid Research, 2001, 42, 1346-1367.	2.0	406
1070	Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. Journal of Lipid Research, 2002, 43, 979-985.	2.0	120
1071	LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. Journal of Lipid Research, 2002, 43, 598-603.	2.0	49
1072	Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia. Journal of Lipid Research, 2000, 41, 245-252.	2.0	58
1073	Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. Journal of Lipid Research, 2000, 41, 305-317.	2.0	192
1074	LDL particle size and LDL and HDL cholesterol changes with dietary fat and cholesterol in healthy subjects. Journal of Lipid Research, 1998, 39, 1799-1804.	2.0	8
1075	An olive oil-rich diet results in higher concentrations of LDL cholesterol and a higher number of LDL subfraction particles than rapeseed oil and sunflower oil diets. Journal of Lipid Research, 2000, 41, 1901-1911.	2.0	77
1076	Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia. Journal of Lipid Research, 2000, 41, 727-733.	2.0	41
1077	Co-ordination of hepatic and adipose tissue lipid metabolism after oral glucose. Journal of Lipid Research, 1999, 40, 2034-2043.	2.0	34
1078	Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. Journal of Lipid Research, 1998, 39, 1263-1273.	2.0	174
1079	Analytical capillary isotachopheresis of total plasma lipoproteins: a new tool to identify atherogenic low density lipoproteins. Journal of Lipid Research, 1999, 40, 170-177.	2.0	25
1080	Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. Journal of Lipid Research, 1993, 34, 1687-1697.	2.0	256
1081	Factors influencing Lp[a]- particle size as determined by gradient gel electrophoresis.. Journal of Lipid Research, 1996, 37, 1655-1663.	2.0	7
1082	Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. Etude Cas TÃ©moin sur l'Infarctus du Myocarde.. Journal of Lipid Research, 1996, 36, 2141-2146.	2.0	125

#	ARTICLE	IF	CITATIONS
1083	Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology. <i>Journal of Lipid Research</i> , 1995, 36, 2291-2302.	2.0	48
1084	Associations of hepatic and lipoprotein lipase activities with changes in dietary composition and low density lipoprotein subclasses.. <i>Journal of Lipid Research</i> , 1995, 36, 462-472.	2.0	110
1085	High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease.. <i>Journal of Lipid Research</i> , 1995, 36, 573-582.	2.0	111
1086	Correlations of plasma lipoproteins with LDL subfractions by particle size in men and women.. <i>Journal of Lipid Research</i> , 1992, 33, 765-774.	2.0	59
1087	Abnormalities of low density lipoproteins in normolipidemic type II diabetic and nondiabetic patients with coronary artery disease.. <i>Journal of Lipid Research</i> , 1992, 33, 333-342.	2.0	30
1088	Different effects of diets rich in olive oil, rapeseed oil and sunflower-seed oil on postprandial lipid and lipoprotein concentrations and on lipoprotein oxidation susceptibility. <i>British Journal of Nutrition</i> , 2002, 87, 489-499.	1.2	14
1089	The multidisciplinary nature of public health genetics in research and education. , 2000, , 83-100.		1
1090	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	1.0	776
1091	Effect of a Reduced-Fat Diet With or Without Pravastatin on Glucose Tolerance and Insulin Sensitivity in Patients with Primary Hypercholesterolemia. <i>Journal of Cardiovascular Pharmacology</i> , 1996, 28, 595-602.	0.8	10
1092	Comorbidities of overweight and obesity: current evidence and research issues. <i>Medicine and Science in Sports and Exercise</i> , 1999, 31, S602.	0.2	212
1093	Defects of lipoprotein metabolism in familial combined hyperlipidaemia. <i>Current Opinion in Lipidology</i> , 1998, 9, 189-196.	1.2	58
1094	Lipoprotein classes and coronary disease regression. <i>Current Opinion in Lipidology</i> , 1998, 9, 329-336.	1.2	21
1095	European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, S1-S78.	3.1	174
1096	Evaluation of Anti-Diabetic and Anti-lipidemic Activities of Aqueous Leaf Extract of <i>Millettia aboensis</i> and Its Effect on Pancreatic Histology of Alloxan-Induced Diabetic Rats. <i>Advances in Biochemistry</i> , 2015, 3, 24.	0.3	3
1097	Diabetic LDL inhibits cell-cycle progression via STAT5B and p21waf. <i>Journal of Clinical Investigation</i> , 2002, 109, 111-119.	3.9	21
1098	Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities.. <i>Journal of Clinical Investigation</i> , 1993, 91, 448-455.	3.9	137
1099	Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles.. <i>Journal of Clinical Investigation</i> , 1993, 92, 141-146.	3.9	610
1100	Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.. <i>Journal of Clinical Investigation</i> , 1993, 92, 160-168.	3.9	176

#	ARTICLE	IF	CITATIONS
1101	Accumulation of "small dense" low density lipoproteins (LDL) in a homozygous patients with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor.. Journal of Clinical Investigation, 1993, 92, 2922-2933.	3.9	69
1102	A unique genetic and biochemical presentation of fish-eye disease.. Journal of Clinical Investigation, 1995, 96, 2783-2791.	3.9	53
1103	Metabolically healthy obesity: facts and fantasies. Journal of Clinical Investigation, 2019, 129, 3978-3989.	3.9	355
1104	Low cholesterol efflux capacity and abnormal lipoprotein particles in youth with type 1 diabetes: a case control study. Cardiovascular Diabetology, 2018, 17, 158.	2.7	25
1106	Dietary, Physiological, and Genetic Impacts on Postprandial Lipid Metabolism. Frontiers in Neuroscience, 2009, , 417-460.	0.0	8
1107	Antioxidant Vitamin Concentrations and LDL Oxidation in Nephrotic Syndrome. , 0, .		2
1108	Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutrition Reviews, 2005, 63, 133-57.	2.6	280
1109	State of the Science on Cardiometabolic Risk After Spinal Cord Injury: Recap of the 2013 ASIA Pre-Conference on Cardiometabolic Disease. Topics in Spinal Cord Injury Rehabilitation, 2014, 20, 105-112.	0.8	6
1110	Effects of a very high saturated fat diet on LDL particles in adults with atherogenic dyslipidemia: A randomized controlled trial. PLoS ONE, 2017, 12, e0170664.	1.1	75
1111	CAN ACROCHORDONS BE A MARKER OF METABOLIC SYNDROME?. Journal of Evolution of Medical and Dental Sciences, 2017, 6, 4183-4187.	0.1	1
1112	Health benefits of polyunsaturated fatty acids (PUFAs). , 2006, , 107-140.		7
1113	Lipoproteínas de alta densidade: aspectos metabólicos, clínicos, epidemiológicos e de intervenção terapêutica. Atualização para os clínicos. Arquivos Brasileiros De Cardiologia, 2006, 87, 671-679.	0.3	22
1114	The Effect of PPAR $\beta$ -Agonism on LDL Subclass Profile in Patients with Type 2 Diabetes and Coronary Artery Disease. Review of Diabetic Studies, 2006, 3, 31-31.	0.5	12
1115	Biochemical Manifestation of HIV Lipodystrophy Syndrome. International Journal of MCH and AIDS, 2012, 1, 92-101.	0.3	2
1116	Ratio of Dense to Buoyant LDL Subclass is Associated with LDL Density Phenotype (VLDL-5). The Open Chemical and Biomedical Methods Journal, 2013, 6, 1-5.	0.5	8
1117	Treatment of Hypertriglyceridemia: a Review of Current Options. Physiological Research, 2015, 64, S331-S340.	0.4	22
1118	A Prospective, Multicentre, Single Arm Clinical Study to Evaluate the Effect of Saroglitazar on Non High-Density Lipoprotein Cholesterol in Patients with Diabetic Dyslipidemia Inadequately Controlled with Diet, Exercise, and Statin-The GLIDDER Study. , 2019, 10, .		1
1119	Comparison of Postprandial Responses to a High-Fat Meal in Hypertriglyceridemic Men and Women before and after Treatment with Fenofibrate in the Genetics and Lipid Lowering Drugs and Diet Network (GOLDN) Study. SRX Pharmacology, 2010, 2010, 1-8.	0.2	3

#	ARTICLE	IF	CITATIONS
1120	Distribution of LDL subgroups in patients with hyperlipidemia. Turkish Journal of Medical Sciences, 2016, 46, 374-380.	0.4	5
1121	High fiber and high carbohydrate intake and its association with the metabolic disease using the data of KNHANES 2013 ~ 2017. Journal of Nutrition and Health, 2019, 52, 540.	0.2	3
1122	Association of Microalbuminuria with Ischemic Heart Disease, Dyslipidemia and Obesity among Diabetic Patients: Experience from 5 Year Follow up Study of 1415 Patients. Bioenergetics: Open Access, 2014, 03, .	0.1	3
1123	High density lipoproteins and type 2 diabetes: Emerging concepts in their relationship. World Journal of Experimental Medicine, 2014, 4, 1.	0.9	15
1124	Life Style and Cardiovascular Risk Factors in the Japanese Population-From an Epidemiological Survey on Serum Lipid Levels in Japan 1990. Part 1: Influence of Life Style and Excess Body Weight on HDL-Cholesterol and Other Lipid Parameters in Men. Journal of Atherosclerosis and Thrombosis, 2003, 10, 165-175.	0.9	26
1125	Small Dense Low-density Lipoprotein Cholesterol is a Useful Marker of Metabolic Syndrome in Patients with Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2007, 14, 202-207.	0.9	27
1126	Arguments In Favor Of Ketogenic Diets. The Internet Journal of Nutrition and Wellness, 2007, 4, .	0.1	4
1127	A Non-Atherogenic and Atherogenic Lipoprotein Profile in Individuals with Dyslipoproteinemia. , 0, , .		2
1128	The rs2070895 (-250G/A) Single Nucleotide Polymorphism in Hepatic Lipase (HL) Gene and the Risk of Coronary Artery Disease in North Indian Population: A Case-Control Study. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, GC01-6.	0.8	6
1129	Health Implications of Obesity. Handbook of Experimental Pharmacology, 2000, , 29-56.	0.9	0
1130	Lipoprotein Metabolism and Atherogenesis. , 2000, , 3-11.		2
1131	Stoffwechsel und endokrine Erkrankungen. , 2000, , 255-310.		0
1133	Hypertriglyceridemia and Low High-Density Lipoprotein: Risks for Coronary Artery Disease?. Journal of Cardiovascular Nursing, 2000, 14, 79-90.	0.6	3
1134	Problemy i perspektivy gipolipidemicheskoy terapii pri sakharnom diabete (Soobshchenie 1). Diabetes Mellitus, 2000, 3, 9-12.	0.5	1
1135	The Mediterranean Diet and Coronary Heart Disease. Modern Nutrition, 2001, , 243-291.	0.1	0
1138	è¾42æîã«ãÑã'ã,ç"ÿæ'æ...£ç—...ã®è‡"ã°Šç—«ã-çš,,ç"ç©¶. Journal of the Japanese Association of Rural Medicine, 2001, 50p580-590.		
1139	Effects of alacepril on low-density lipoprotein particle size in patients with essential hypertension. The Journal of Japan Atherosclerosis Society, 2002, 29, 63-68.	0.0	0
1140	Dyslipidemia and Cardiovascular Risk in Diabetes. , 2003, , 53-62.		1

#	ARTICLE	IF	CITATIONS
1141	Comparison of Low-Density Lipoprotein Size by Polyacrylamide Tube Gel Electrophoresis and Polyacrylamide Gradient Gel Electrophoresis. <i>American Journal of Clinical Pathology</i> , 2003, 119, 0-0.	0.4	0
1144	Weight Loss and Metabolic Diseases. , 2004, , 195-215.		0
1145	Fatty Acids, Gene Expression, and Coronary Heart Disease (CHD). <i>Oxidative Stress and Disease</i> , 2005, , 181-200.	0.3	0
1146	New Insights on the Role of Lipids and Lipoproteins in Cardiovascular Disease. , 2005, , 211-263.		0
1147	The Metabolic Syndrome: Identification and Management of the Patient at High Risk for Cardiovascular Disease. <i>Fundamental and Clinical Cardiology</i> , 2006, , 409-440.	0.0	0
1148	Dairy Foods and Cardiovascular Health. , 2006, , 55-98.		0
1149	Prediction of Global Cardiovascular Risk in Hypertension. , 2007, , 190-198.		0
1150	Pathophysiology and Management of Dyslipidemias Associated with Obesity, Type 2 Diabetes, and Other Insulin-Resistant States. , 2007, , 55-68.		0
1151	Management of Cholesterol Disorders. , 2007, , 2667-2691.		0
1152	Utilization of Lipoprotein Subfractions. , 2007, , 321-347.		0
1153	Postprandial Hyperglycemia. , 2008, , 97-113.		0
1154	Evaluation of qualitative alteration in LDL particles by LDL relative mobility using agarose gel electrophoresis. <i>Juntendoi, Igaku</i> , 2008, 54, 61-66.	0.1	0
1155	Insulin Resistance and Dyslipidemia. , 2008, , 205-218.		0
1156	Biochemical Aspects, Laboratory Diagnosis and Follow-Up of High Blood Cholesterol: NCEP ATP III Guidelines. <i>Journal of Medical Biochemistry</i> , 2008, 27, 64-85.	0.7	0
1157	The Effects of Exercise Intensity on the Low-Density Lipoprotein Profile: Quantitative vs. Qualitative Changes. <i>Journal of Biological Sciences</i> , 2008, 8, 335-341.	0.1	0
1158	The parameters related to small dense low-density lipoprotein evaluated by non-denaturing polyacrylamide gel electrophoresis method in dyslipidemic subjects: with reference to the Japanese guideline for prevention of atherosclerotic cardiovascular diseases. <i>Journal of Electrophoresis</i> , 2009, 53, 39-43.	0.2	0
1159	Cardiovascular Effects of Obesity. , 2009, , 1-11.		0
1160	Residual Risk Reduction Initiative: vÃ½zva ke snÃ¼4enÃ½-reziduÃ½lnÃ½ho vaskulÃ½rnÃ½ho rizika u pacientÃ½ s dyslipidemiÃ½. <i>Cor Et Vasa</i> , 2010, 52, 212-228.	0.1	0

#	ARTICLE	IF	CITATIONS
1161	The Metabolic Syndrome: 2009. , 2011, , 137-163.		0
1162	Advanced Lipid Testing. , 2011, , 77-103.		0
1163	Small Dense Low-density Lipoprotein and Cardiovascular Disease. Journal of Lipid and Atherosclerosis, 2012, 1, 1.	1.1	0
1164	Impact of the Glucolipototoxicity In vivo and Insulinotoxicity Inducing in Fibroblast Aortic of Sand Rat (Psammomys obesus). Journal of Diabetes & Metabolism, 2012, 03, .	0.2	0
1165	Clinical Aspects of Gout and Associated Disease States. , 2013, , 91-185.		3
1166	Size of low-density lipoprotein particles in patients after stroke. Polish Archives of Internal Medicine, 2012, 122, 30-31.	0.3	0
1167	Comparing the effect of lovastatin and exercise on serum lipid profile in hyperlipidaemic patients. International Journal of Medicine and Biomedical Research, 2013, , 18-22.	0.0	1
1168	CVD in CKD: Focus on the Dyslipidemia Problem. , 2014, , 67-91.		0
1169	Importance of high triglycerides as a cardiovascular risk factor in Indian diabetic population and #8211; A review. International Journal of Medical Science and Public Health, 2014, 3, 781.	0.2	0
1170	Dairy Foods and Cardiovascular Health. , 1999, , .		0
1171	The Relationship between Small, Low-Density Lipoprotein Particles and Plasma Lipids, Obesity, and Insulin Sensitivity in Patients with Glucose Intolerance. The Journal of Japan Atherosclerosis Society, 1992, 20, 899-907.	0.0	0
1172	Fibrates and Reversal of Atherogenic Particles. Medical Science Symposia Series, 1992, , 255-258.	0.0	0
1173	Plasma Triglyceride and Coronary Heart Disease. Medical Science Symposia Series, 1992, , 229-233.	0.0	0
1174	Whither Triglycerides in the Cholesterol Campaign. Medical Science Symposia Series, 1992, , 225-228.	0.0	0
1175	Lipid Metabolism and its Disorders in Diabetes Mellitus. Developments in Cardiovascular Medicine, 1992, , 111-139.	0.1	0
1176	Restenosis Following Laser Angioplasty. Developments in Cardiovascular Medicine, 1992, , 385-413.	0.1	0
1177	Atherogenicity of Triglyceride-Rich Lipoproteins: Clinical Aspects. Medical Science Symposia Series, 1993, , 453-466.	0.0	0
1178	Postprandial Hyperlipidemia and Coronary Artery Disease. Medical Science Symposia Series, 1993, , 69-74.	0.0	1

#	ARTICLE	IF	CITATIONS
1179	Low Density Lipoprotein Subclass Phenotypes. Developments in Cardiovascular Medicine, 1994, , 105-113.	0.1	1
1180	The Significance of Small Low Density Lipoprotein (LDL) as a Risk Factor for Coronary Artery Disease (CAD) in Non-diabetic and Normocholesterolemic Subjects. The Journal of Japan Atherosclerosis Society, 1995, 22, 841-847.	0.0	0
1181	Dyslipidemia in Niddm: New Insights. Medical Science Symposia Series, 1995, , 165-172.	0.0	0
1182	Ambulante Langzeitrehabilitation am Wohnort. , 1995, , 508-521.		1
1183	Triglycerides are Independently Predictive of the Extent of Coronary Atherosclerosis. Medical Science Symposia Series, 1996, , 195-201.	0.0	0
1184	Lipidaemia and Diabetic Renal Disease. , 1996, , 307-320.		0
1185	Emerging Evidence for Triglyceride As A Risk Factor for Coronary Artery Disease: A Review of the Epidemiologic Data. Medical Science Symposia Series, 1996, , 187-194.	0.0	0
1186	Insulin Resistance and Lipoproteins in Hypertriglyceridemia: Effects of Hypolipidemic Drug Treatment. Medical Science Symposia Series, 1996, , 389-396.	0.0	0
1187	Epidemiology and risk factors of coronary artery disease. Developments in Cardiovascular Medicine, 1996, , 139-166.	0.1	0
1188	Management of Primary Hyperlipidemia with Combination Therapy. Medical Science Symposia Series, 1996, , 497-504.	0.0	0
1190	Assessment of Lipoproteins. , 1997, , 170-217.		1
1191	Approaches for the Design of Novel Anti-Atherogenic Compounds. Sub-Cellular Biochemistry, 1997, 28, 507-539.	1.0	0
1192	Analysis of HDL subfraction from patients with polydisperse LDL. The Journal of Japan Atherosclerosis Society, 1997, 25, 155-165.	0.0	0
1193	Is Hypertriglyceridemia always a Risk Factor?. Developments in Cardiovascular Medicine, 1997, , 133-160.	0.1	0
1194	Lipidaemia and Diabetic Renal Disease. , 1998, , 357-369.		2
1195	Cholesterol Lowering. Contemporary Cardiology, 1999, , 571-592.	0.0	0
1196	Lipid Lowering Therapy. Developments in Cardiovascular Medicine, 1999, , 69-101.	0.1	0
1197	Effects of Three Different Modes of Exercise Training on Plasma Lipoprotein Profile in Healthy Men. British Journal of Medicine and Medical Research, 2015, 6, 493-499.	0.2	0

#	ARTICLE	IF	CITATIONS
1200	Cardiovascular Risk Factors among Malaysian Diabetic Patients. International Archive of Medicine, 0, , .	1.2	0
1201	Metabolic Associations with Skin Tags. International Journal of Dermatology and Clinical Research, 0, , 003-011.	0.4	1
1202	Options and Alternatives. , 2017, , 65-90.		0
1203	Internist, anesthesiologist and surgeon use of ketogenic diet. Minerva Gastroenterology, 2017, 64, 84-93.	0.3	1
1204	Diabetes and Dislipidemia. Endocrinology, 2018, , 51-70.	0.1	0
1205	Disparity in fasting plasma cholesterol and abdominal adiposity within and between genders in Lagos Southwest Nigeria. Endocrinology&Metabolism International Journal, 2018, 6, .	0.1	0
1206	Diabetes and Dyslipidemia. Endocrinology, 2019, , 1-20.	0.1	0
1207	Diabetes and Dyslipidemia. Endocrinology, 2019, , 1-20.	0.1	0
1208	Role of non-HDL-cholesterol in evaluation of dyslipidemia in preeclampsia. International Journal of Clinical Biochemistry and Research, 2019, 6, 369-374.	0.0	0
1209	Prevalence of atherogenic dyslipidemia in young asymptomatic medical professionals of a Tertiary Care Hospital in South India: A cross-sectional study. International Journal of Clinical Biochemistry and Research, 2020, 7, 403-407.	0.0	1
1210	Low-density lipoprotein cholesterol/apolipoprotein B ratio is superior to apolipoprotein B alone in the diagnosis of coronary artery calcification. Coronary Artery Disease, 2021, 32, 561-566.	0.3	7
1211	Ion Mobility Lipoprotein Analysis. Contemporary Cardiology, 2021, , 537-544.	0.0	0
1213	Diabetes and Dyslipidemia. Endocrinology, 2020, , 51-70.	0.1	0
1214	Study of Lipid Abnormalities in Type 2 Diabetes Mellitus Patients with Nephropathy in Eastern India. Journal of Diabetes Mellitus, 2020, 10, 16-25.	0.1	1
1215	Diabetic LDL inhibits cell-cycle progression via STAT5B and p21waf. Journal of Clinical Investigation, 2002, 109, 111-119.	3.9	8
1217	The insulin resistance-dyslipidemia syndrome: the most prevalent cause of coronary artery disease?. Cmaj, 1993, 148, 1339-40.	0.9	0
1218	Both inherited susceptibility and environmental exposure determine the low-density lipoprotein-subfraction pattern distribution in healthy Dutch families. American Journal of Human Genetics, 1992, 51, 1295-310.	2.6	56
1219	Multilocus genetic determinants of LDL particle size in coronary artery disease families. American Journal of Human Genetics, 1996, 58, 585-94.	2.6	65

#	ARTICLE	IF	CITATIONS
1220	Statins in type 2 diabetes mellitus: target on lipids and vascular wall function. <i>Netherlands Heart Journal</i> , 2003, 11, 123-128.	0.3	0
1224	High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need. <i>Translational Medicine @ UniSa</i> , 2015, 12, 29-40.	0.8	4
1225	In vitro and in vivo effects of ethanol extract combined with <i>Curcumae Radix</i> and <i>Glycyrrhizae Radix et Rhizoma</i> on menopausal metabolic disturbances. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 15076-86.	1.3	4
1228	The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus. <i>Metabolites</i> , 2021, 11, 807.	1.3	17
1229	Metabolism of Triglyceride-Rich Lipoproteins. <i>Handbook of Experimental Pharmacology</i> , 2021, , 133-156.	0.9	6
1230	Phytonutrients of Bitter Apricot Seeds Modulate Human Lipid Profile and LDL Subfractions in Adults with Elevated Cholesterol Levels. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 857.	1.2	4
1231	Association of adolescent lipoprotein subclass profile with carotid intima-media thickness and comparison to adults: Prospective population-based cohort studies. <i>Atherosclerosis</i> , 2022, 341, 34-42.	0.4	1
1232	Association between functional foods and cardiometabolic health in a real-life setting: a longitudinal observational study using objective diet records from an electronic purchase system. <i>Food and Function</i> , 2022, , .	2.1	1
1233	TO STUDY THE SERUM LIPID PROFILE IN ISCHEMIC AND HEMORRHAGIC STROKE AMONG THE PATIENTS IN TERTIARY HEALTH CENTRE. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 131-134.	0.3	0
1234	The Pattern of Dyslipidaemia and Factors Associated With Elevated Non-HDL-Cholesterol Levels Among Patients With Type 2 Diabetes Mellitus in the Ho Municipality: A Cross Sectional Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1235	Relationship between Apolipoprotein E Genotype and Lipoprotein Profile in Patients with Coronary Heart Disease. <i>Molecules</i> , 2022, 27, 1377.	1.7	2
1236	The world congress on insulin resistance, diabetes, and cardiovascular disease ( <sc>WCIRDC</sc>) Tj ETQq1 1 0,784314 rgBT /Ovrl	0.8	0
1237	Triglycerides. <i>Medical Clinics of North America</i> , 2022, 106, 299-312.	1.1	2
1238	Examining the Efficacy of a Very-Low-Carbohydrate Ketogenic Diet on Cardiovascular Health in Adults with Mildly Elevated Low-Density Lipoprotein Cholesterol in an Open-Label Pilot Study. <i>Metabolic Syndrome and Related Disorders</i> , 2022, 20, 94-103.	0.5	6
1239	Small dense low-density lipoprotein particles: clinically relevant?. <i>Current Opinion in Lipidology</i> , 2022, 33, 160-166.	1.2	16
1240	The Clinical Significance of Small, Dense Low-Density Lipoproteins. , 2006, , 168-185.		0
1244	When and what to eat? A scoping review of health outcomes of fasting in conjunction with a low-carbohydrate diet. <i>British Journal of Nutrition</i> , 2023, 129, 1677-1692.	1.2	2
1245	Banting memorial lecture 2022: â€ˆType 2 diabetes and nonalcoholic fatty liver disease: Partners in crimeâ€™™. <i>Diabetic Medicine</i> , 2022, 39, .	1.2	9

#	ARTICLE	IF	CITATIONS
1246	LDL retention time in plasma can be -based on causation- estimated by the lipid composition of LDL and other lipoproteins. PLoS ONE, 2022, 17, e0272050.	1.1	1
1247	The pattern of dyslipidaemia and factors associated with elevated levels of non-HDL-cholesterol among patients with type 2 diabetes mellitus in the Ho municipality: A cross sectional study. Heliyon, 2022, 8, e10279.	1.4	4
1248	LIPID DISORDERS IN TYPE 2 DIABETES. Nursing Clinics of North America, 2001, 36, 291-302.	0.7	3
1249	Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9. Pharmacological Research, 2022, 184, 106439.	3.1	10
1250	Association of rs662799 and rs5070 genetic polymorphisms with hypertriglyceridemia and atherogenic dyslipidemia in pediatric patients in Southeast Mexico. Clínica E Investigaci3n En Arteriosclerosis, 2023, 35, 53-63.	0.4	0
1251	The influence of somatic maturity on the relationship between the triglyceride/high-density lipoprotein ratio and vascular health in children and adolescents with dyslipidemia. American Journal of Human Biology, 0, , .	0.8	0
1252	LDL size: does it matter?. Swiss Medical Weekly, 0, , .	0.8	13
1253	Plasma LDL subtype distribution in patients with or without coronary stenosis. Turkish Journal of Medical Sciences, 0, , .	0.4	4
1257	The predictive value of nontraditional lipid parameters for intracranial and extracranial atherosclerotic stenosis: a hospital-based observational study in China. Lipids in Health and Disease, 2023, 22, .	1.2	2
1258	Nonalcoholic fatty liver disease and cardiovascular disease. , 2023, , 11-16.		0
1259	CME Credit Article: Does Hypertriglyceridemia Increase Risk for CAD?: Growing Evidence Suggests it Plays a Role. Postgraduate Medicine, 2000, 108, 77-84.	0.9	5
1261	Atherosclerotic cardiovascular disease risk and small dense low-density lipoprotein cholesterol in men, women, African Americans and non-African Americans: The pooling project. Atherosclerosis, 2023, 367, 15-23.	0.4	5
1262	Primary Treatment Effects for High-Grade Serous Ovarian Carcinoma Evaluated by Changes in Serum Metabolites and Lipoproteins. Metabolites, 2023, 13, 417.	1.3	1
1263	The Oxidized Lipoproteins In Vivo: Its Diversity and Behavior in the Human Circulation. International Journal of Molecular Sciences, 2023, 24, 5747.	1.8	5
1264	Exploring the Association between Low-Density Lipoprotein Subfractions and Major Adverse Cardiovascular Outcomesâ€”A Comprehensive Review. International Journal of Molecular Sciences, 2023, 24, 6669.	1.8	4
1265	Small Dense LDL Level and LDL/HDL Distribution in Acute Coronary Syndrome Patients. Biomedicines, 2023, 11, 1198.	1.4	3
1270	Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Patients with Diabetes Mellitus Type 2. Contemporary Diabetes, 2023, , 637-679.	0.0	0
1271	Understanding human diet, disease, and insulin resistance: scientific and evolutionary perspectives. , 2023, , 3-69.		0

#	ARTICLE	IF	CITATIONS
1286	Genetics of Lipid Disorders. , 2023, , 163-195.		0